SCORE Search Results Details for Application 10536880 and Search Result 20070125\_140747\_us-10-5... Page 1 of 16

SCORE Search Results Details for Application 10536880 and Search Result 20070125\_140747\_us-10-5... Page 2 of 16

### SCORE Search Results Details for Application 10536880 and Search Result 20070125\_140747\_us-10-536-880a-27.rag.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10536880 and Search Result 20070125\_140747\_us-10-536-880a-27.rag.

start | next page

Go.Back, to previous page

```
GenCore version 6.2
Copyright (c) 1993 - 2007 Biocceleration Ltd.
```

OM protein - protein search, using sw model

January 28, 2007, 08:29:27 ; Search time 216 Seconds (without alignments) 67.963 Million cell updates/sec

ë

Run

US-10-536-880A-27 Title:

150 1 HSDAIFTDSYSRYRRQLAVRRYLAAVLGRR 30 Perfect score: Sequence:

Gapop 10.0 , Gapext 0.5 BLOSUM62 Scoring table:

2782304 segs, 489333398 residues Searched:

2782304 Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0% Maximum Match 100% Listing first 45 summaries

A\_Geneseq\_200701:\* Database

geneseqp1990s:\* geneseqp1980s

geneseqp2002s:\* geneseqp2001s: geneseqp2000s

geneseqp2003as: geneseqp2003bs:

geneseqp2004s:\* geneseqp2005s:\*

geneseqp2006s:\* geneseqp2007s: 10:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Description sult Query No. 'Score Match Length DB Result

http://es/ScoreAccessWeb/GetItem.action?AppId=10536880&seqId=1073663&ItemName=20070125\_14... 1/30/2007

Vasoactiv Bronchodi Retinal d Vasoactiv Bronchodi Novel ant Retinal d Synthetic Vasoactiv Vasoactiv Novel ant Pituitary Novel ant Vasoactiv Pituitary tuitary Pituitary Neurotoxi Novel ant Conformat Conformat Neurotoxi PACAP/VIE Conformat Veurite Neurite Neurite Adp09605 Adr05664 Adt88479 Aed86828 Adp09603 Adr05661 A Adt88476 Adp09606 Adf54730 1 Abb07022 1 Adb61594 0 Adf54717 1 Adp09582 1 Aed86825 Aed86832 Abb07020 Adb61606 Adf54729 Adp43320 Adr05663 Aed86826 Aaw10335 Adp43319 Adr05665 Adt88480 Aed86829 Aaw10334 Adb61607 Adr05659 Aay05444 Aaw10333 Aab92124 4DR05663 **AED86826** ADP43319 ADR05664 ADB61594 4DF54717

**ALIGNMENTS** 

```
vasoactive intestinal peptide, VIP; bronchus smooth muscular relaxation; gastrointestinal-tract movement suppression;
                                                                                                                                                         pituitary adenylate cyclase activating polypeptide; PACAP;
                                                                                                                          PACAP/VIP derived peptide sequence SeqID 29.
                               ADP09604 standard; peptide; 30 AA.
                                                                                            (first entry)
                                                                                            26-AUG-2004
                                                             ADP09604;
RESULT 1
                ADP09604
```

http://es/ScoreAccessWeb/GetItem.action?AppId=10536880&seqId=1073663&ItemName=20070125\_14... 1/30/2007

optic-nerve degenerative disease; retina degenerative disease;

# SCORE Search Results Details for Application 10536880 and Search Result 20070125\_140749\_us-10-5... Page 2 of 13

sardinops m

Q75w90

### SCORE Search Results Details for Application 10536880 and Search Result 20070125\_140749\_us-10-536-880a 27.rup.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10536880 and Search Result 20070125\_140749\_us-10-536-880a-27.rup.

GenCore version 6.2 Copyright (c) 1993 - 2007 Biocceleration Ltd

January 28, 2007, 08:33:06 ; Search time 345 Seconds OM protein - protein search, using sw model ::0

Run

93.228 Million cell updates/sec (without alignments)

US-10-536-880A-27 Perfect score: ritle:

1 HSDAIFTDSYSRYRRQLAVRRYLAAVLGRR 30 Sequence:

Gapop 10.0 , Gapext 0.5 BLOSUM62 Scoring table:

s pituitary o pituitary

h pituitary

homo sapien

eriocheir j

9EUCA

Q5XJ02 BRARE Q98TU3\_BRARE

**075W93** 

D52LQ0 HUMAN

brachydanio brachydanio

Q5xj02 Q98tu3

ALIGNMENTS

RESULT 1

Q75w93

mus musculu

Q53bh Q53bh Q5iflo Q5ifk8 Q5g7m0 Q8bjt8 Q09169 Q9puf8

homo sapien pan troglod pan troglod macaca fasc

saimiri bol

9PRIM MACFA

PANTR PANTR

**053BH0** 

Go\_Back\_to\_previous\_page.

oryctolagus

oncorhynchu

bunopithecu macaca mula

Q8ayp4 Q8ayp5 Q1zzb9 Q53bi4 Q53bi3 Q53bi5 Q53bi5 Q53bi2 Q53bi2 Q53bi2 Q53bi2

podarcis si pongo pygma

PODSI BUNHO

053BI4

TRAJP

MACMU 9PRIM RABIT

PONPY

trachurus

tetraodon n

m pituitary mus musculu b pituitary

Q98sp5 O70176 P13589 Q3uyh8 Q29w19 P18509 P41535 P16613 Q521q0 Q75w88

r pituitary

oncorhynchu

xenopus lae

r glucagon

PACA\_RANRI Q9PUF8\_XENLA

MOUSE

24 RN1 9\_TETNG

PACA ONCINE

ONCH

**398SP5** 

PACA MOUSE

D3UYH8 MOUSE

PACA\_BOVIN

PACA HUMAN PACA SHEEP

Total number of hits satisfying chosen parameters:

3281787 seqs, 1072124677 residues

Searched:

Minimum DB seq length: 0 Maximum DB seq length: 200000000

Post-processing: Minimum Match 0% Maximum Match 100% Listing first 45 summaries

UniProt\_8.4:\*
1: uniprot\_sprot:\*
2: uniprot\_trembl:\* Database

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

### \*\* di Result

Description	Q90xz4 ictalurus p	P48144 clarias mac	P81039 uranoscopus	Q75w89 sebastiscus	Q4rh43 tetraodon n	Q75w94 halocynthia	Q8iu37 sepioteuthi	Q8iu36 periplaneta
ID	Q90XZ4_ICTPU	1 PACA CLAMA	PACA URAJA	Q75W89_9PERC	Q4RH43_TETNG	Q75W94_HALRO	Q8IU37_SEPLE	Q8IU36_PERAM
8	7	-	-	7	~	~	7	~
Score Match Length DB ID	175	195	38	38	170	38	38	38
Match	90.06	90.0	89.3	89.3	89.3	88.0	88.0	88.0
Score	. 135 90.0 175	135	134	134	134	132	132	132
No.	7	7	m	4	ß	ø	7	œ

http://es/ScoreAccessWeb/GetItem.action?AppId=10536880&seqId=1073664&ItemName=20070125\_14... 1/30/2007

http://es/ScoreAccessWeb/GetItem.action?Appid=10536880&seqId=1073664&ItemName=20070125\_14... 1/30/2007

# SCORE Search Results Details for Application 10536880 and Search Result 20070125\_140752\_us-10-5... Page 2 of 14

VRHU -

170

67.0

100.5

12

SCORE Search F

vasoactive intesti

# Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10536880 and Search Result 20070125\_140752\_us-

GenCore version 6.2 Copyright (c) 1993 - 2007 Biocceleration Ltd.

January 28, 2007, 08:36:42 ; Search time 39 Seconds OM protein - protein search, using sw model Run on:

(without alignments)
74.013 Million cell updates/sec

US-10-536-880A-27 Title: Perfect score: Sequence:

1 HSDAIFTDSYSRYRRQLAVRRYLAAVLGRR 30

Gapop 10.0 , Gapext 0.5 Scoring table:

283416 segs, 96216763 residues Searched:

283416 Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 04 Maximum Match 1004 Listing first 45 summaries

pirl:\* pir2:\* pir3:\* PIR\_80:\* Database :

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

Description	pituitary adenylat	pituitary adenylat	neuropeptides prec	pituitary adenylat	vasoactive intesti	vasoactive intesti	vasoactive intesti				
QI	I50456	A49165	534767	A37786	184638	A34044	A61070	A61071	VRCH	VRPG	A60038
08	7	7	7	~	~	~	~	~	~	-	7
Query Match Length DB	195	38	173	175	176	176	38	27	165	58	145
Query Match	90.0	88.0	88.0	88.0	88.0	88.0	84.0	79.3	72.3	67.0	67.0
Score	135	132	132	132	132	132	126	119	108.5	100.5	100.5
Result No.	1	~	Э	•	s	9	7	89	Ø	10	11

1/30/2007 http://es/ScoreAccessWeb/GetItem.action?AppId=10536880&seqId=1073665&ItemName=20070125\_14...

13	100.5	67.0	170	-	VRRT	Vascactive intesti
14	100.5	67.0	170	. ~	A60037	
15	86	65.3	28	7	B60071	vasoactive intesti
16	86	65.3	28	7	A60304	vasoactive intesti
17	98	65.3	25	н	VRBO	vasoactive intesti
18	86	65.3	55	-	VRRB	vasoactive intesti
19	98	65.3	ន	Н	VRSH	vasoactive intesti
20	97	64.7	28	7	A60303 .	vasoactive intesti
21	95	63.3	25	~	JQ0361	vasoactive intesti
22	95	63.3	25	Н	VRGP	vasoactive intesti
23	94	62.7	28	~	A38232	vasoactive intesti
24	92	61.3	35	Н	нменр	exendin-2 - Gila m
25	16	50.7	38	-	HWGHS	exendin-1 - Mexica
56	69	46.0	104	7	A32731	somatoliberin prec
27	64	42.7	44	H	RHBOS	somatoliberin - bo
28	64	42.7	44	н	RHPG	somatoliberin - pi
59	64	42.7	108	Н	RHHUS	somatoliberin prec
30	9	40.0	131	Н	SEPG	secretin precursor
31	58	38.7	133	7	JC2202	secretin precursor
32	98	37.3	27	н	SECH	secretin - chicken
33	26	37.3	134	N	A40959	secretin precursor
34	55	36.7	103	N	A41410	somatoliberin prec
35	53	35.3	127	N	E95298	conserved hypothet
36	52	34.7	289	~	B86955	conserved hypothet
37	52	34.7	324	7	873000	hypothetical prote
38	50.5	33.7	957	~	T15976	hypothetical prote
39	20	33.3	31	7	S44472	glucagon G2 - Nort
40	49.5	33.0	168	7	AE0055	probable lipoprote
41	49	32.7	27	N	A27267	secretin - dog
42	49	32.7	421	0	C83147	gamma-glutamyl pho
43	49	32.7	636	7	T10569	probable serine/th
4	49	32.7	772	N	066690	transcription regu
45	48.5	32.3	252	N	F87259	hypothetical prote

### AL IGNMENTS

```
C;Date: 04-Sep-1997 #sequence_revision 04-Sep-1997 #text_change 09-Jul-2004
C;Accession: I50456
R;MCROTY, J.E.; Parker, D.B.; Ngamvongchon, S.; Sherwood, N.M.
R.J. Cell. Endocrinol. 108, 169-177, 1995
A;Title: Sequence and expression of CDNA for pituitary adenylate cyclase activating polypeptide (PPA;Reference number: I50456; MUID:95278612; PMID:7758831
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  A,Cross-references: UNIPROT:P48144; UNIPARC:UPI00001311D3; EMBL:X79078; NID:9808949; PIDN:CAA55684.
pituitary adenylate cyclase activating polypeptide - Siamese catfish C;Species: Clarias macrocephalus (Siamese catfish)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             90.0%; Score 135; DB 2; Length 195; 83.3%; Pred. No. 2e-12; Live 4; Mismatches 1; Indels
                                                                                                                                                                                                                                                                                                                                                                 A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mENA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Query Match
Best Local Similarity 83.3*
Matches 25; Conservative
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            C, Superfamily: glucagon
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  C, Keywords: duplication
                                                                                                                                                                                                                                                                                                                                                                                                                                                A;Residues: 1-195 <MCR>
                                                                                                                                                                                                                                                                                                                           A;Accession: I50456
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  A;Gene: PACAP
```

### 1 HSDAIFTDSYSRYRRQLAVRRYLAAVLGRR 30 ò

ö

Gaps

ö

http://es/ScoreAccessWeb/GetItem.action?AppId=10536880&seqId=1073665&ItemName=20070125\_14... 1/30/2007

FILE 'REGISTRY' ENTERED AT 12:18:30 ON 30 JAN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STY CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS) -> file registry

Property values tagged with IC are from the 21C/VINITI data file provided by InfoChem.

HIGHEST RN 918776-45-1 HIGHEST RN 918776-45-1 29 JAN 2007 29 JAN 2007 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches

predicted properties as well as tags indicating availability of experimental property data in the original document. For information REGISTRY includes numerically searchable data for experimental and on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d L8 rn cn sql nte lc kwic 1-30

ANSWER 1 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 8 Z Z

REGISTRY 868368-05-2

L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-satyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-leucyl-L-leucyl-L-arginyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-valyl-L-leucyl-L-salanyl-L-val  $L-Argininamide,\ L-histidyl-L-seryl-L-\alpha-aspartyl-L-alanyl-L-isoleucyl-L-alanyl-$ 

modified

C-terminal amide description description ----- location ---------- location -----CA, CAPLUS Arg-30 STN Files: terminal mod. modified type

1 HSDAIFTDSY SRYRRQLAVR RYLAAVLGRR SEO

C-terminal amide

Arg-30

terminal mod.

1-25 HITS AT: \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

ANSWER 2 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 868368-04-1 REGISTRY R LB

### 10/536880

Ü	L-Argininam	ide, L-histidyl-L-seryl-	L-Argininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-
	L-phenylalaı arginyl-L-ty valyl-L-arg L-leucylglyı arginyl-L-vy	nyl.L.threonyl.L.d.aspar yrosyl.L.arginyl.L.targin inyl.L.arginyl.L.tyrosyl cyl.L.arginyl.L.arginyl.	L.phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L- arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L- valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl- L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L- arginyl-L-valyl-L-arginyl-L-asparaginyl- (9CI) (CA INDEX NAME)
SOL			
type	υ	location	description
termi	terminal mod.	Arg-38	C-terminal amide
LC	STN Files: modified	CA, CAPLUS	
type		location	description
term	terminal mod.	Arg-38 -	C-terminal amide

# 1 HSDAIFTDSY SRYRROLAVR RYLAAILGRR YRORVRNR

SEQ

HITS AT:

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

ANSWER 3 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

valy1-L-arginy1-L-arginy1-L-tyrosy1-L-leucy1-L-alany1-L-alany1-L-valy1-L- $\label{local-condition} L-phenylalanyl-L-throuyl-L-arginyl-L-seryl-L-arginyl-L-tyrosyl-L-argin$ L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucylleucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L-arginyl-L-valyl-L-arginyl-L-asparaginyl- (9CI) (CA INDEX NAME) 868368-03-0 REGISTRY modified C R L

description ..... location type

C-terminal amide

description ..... lòcation ..... type

CA, CAPLUS

STN Files:

NTE modified

Arg-38

terminal mod.

C-terminal amide Arg-38 terminal mod.

1 HSDAIFTDSY SRYRRQLAVR RYLAAVLGRR YRQRVRNR SEO

HITS AT:

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

ANSWER 4 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN L8 RN

L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-868368-02-9 REGISTRY

valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-seryl-L-tyrosyl-L-eryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaninyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-ieucyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) description C-terminal amide description C-terminal amide N-acetyl ----- location ---------- location CA, CAPLUS Arg-30 Arg-30 His-1 STN Files: modified LC STN Filer NTE modified terminal mod. terminal mod. terminal mod. type type

# SEQ 1 HSDAVFTDSY SRYRRQLAVR RYLAAVLGRR

HITS AT: 1-25

# \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L8 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 86836-97-9 REGISTRY
CN L-ARGINIAMMIGE, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-d-aspartyl-L-seryl-L-tyrosyl-L-seryl-Larginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glucaminyl-L-leucyl-L-alanyl-Lvalyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucylL-leucylghycyl-L-arginyl- (9CI) (CA INDEX NAME)
son. 30

E modified

type terminal mod. Arg-10 C-terminal amide

LC STN Files: CA, CAPLUS

NTE modified

type description

# SEQ 1 HSDAVFTDSY SRYRRQLAVR RYLAAILGRR

C-terminal amide

Arg-30

terminal mod.

## HITS AT: 1-25

L8 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 868367-91-3 REGISTRY

L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-Gutamyl-L-asparaginyl-L-tyrosyl-Lthreonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-tylutaminyl-L-leucyl-Lalanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-Lisoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

3

10/536880

SQL 30 NTE modified

descrip	terminal mod. Arg-30 - C-terminal amide	STN Files: CA, CAPLUS modified	pe descri	terminal mod. Arg-30 C-terminal amide	1 HSDAVFTENY TRLRRQLAVR RYLAAILGRR	.S AT: 1-25	**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	ANSWER 7 OF 30 REGISTRY COPYRIGHT 2007 ACS on STW 868367-70-8 REGISTRY	.a c J a		pe location descri	ninal mod. His-1 . N'acetyl ninal mod. Arg-30 . C-terminal amide	STN Files: CA, CAPLUS . modified	descri	nal mod. Arg-30	1 HSDAVFTDNY TRLRRQLAVR RYLAAILGRR	**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	ANSWER 8 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 868367-65-1 REGISTRY	<pre>L-Argininamide, L-histidyl-L-seryl-L-G-aspartyl-L-alanyl-L-valyl-L- phenylalanyl-L-threonyl-L-G-aspartyl-L-asparaginyl-L-tyrosyl-L- threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L- alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L- isoleucyl-L-leucylalycyl-L-arginyl-(9CI) (CA INDEX NAME)</pre>	
type	termi	LC	type	termi	SEQ	HITS	**REL	L8 RN	ž č	SQL	type	termi	LC	type	termi	7 S	**REI	RN S	Š	į

typ	ype location	description
term	minal mod. Arg-30 C-	nal amide
NTE	STN Files: modified	
typ	pe	description
term	minal mod. Arg-30	
SEQ	1 HSDAVETDNY TRLRRQ	
HITS		
* * RE	**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
L'8 RN	ANSWER 9 OF 30 REGISTRY COPYRIGHT 2007 ACS 735801-36-2 REGISTRY	on STN
Z U		/l-L-alanyl-L-isoleucyl-
SQL	L-phen arginy valyl- L-leuc arginy 38 modifi	-L-tyrosyl-L-seryl-L- inyl-L-leucyl-L-alanyl-L- -alanyl-L-alanyl-L-isoleucyl- -arginyl-L-glutaminyl-L- (CA INDEX NAME)
t.	pe	description
tern	minal mod. Arg-38 - C	-terminal amide
LC	STN Files: CA, CAPLUS modified	
ţ.	pe location d	escription
term	terminal mod. Arg-38 - C-terminal	nal amide
SEQ	1 HSDAIFTDSY SRYRRQLAVR	ĸ
HITS	HITS AT: 1-25	
**RE	**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
RN RN	ANSWER 10 OF 30 REGISTRY COPYRIGHT 2007 ACS 735801-35-1 REGISTRY	on STN
ž	L-Argininamide, L-histidyl-L-seryl-L- L-phenylalanyl-L-threonyl-L-α-sparty arginyl-L-tyrosyl-L-arginyl-L-arginyl	α-aspartyl-L-alanyl-L-isoleucyl- l-L-seryl-L-tyrosyl-L-seryl-L- -L-qlucaminyl-L-leucyl-L-alanyl-L-
SQL	valyl-L-arginyl-L-arginyl-L-tyrosyl-L leucylglycyl-L-arginyl-L-arginyl-L-ty arginyl-L-valyl-L-arginyl-L-asparagin 38 modified	u-alanyl-L-alanyl-L-valyl-L- irginyl-L-glutaminyl-L- (CA INDEX NAME)
!		: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Comparison   Continue   Continu		
### C. CEPHINS    Files: CA, CAPIUS   Files: C	type	location
Emodified  modified  The modif	terminal mod.	. C-terminal
THE SEQUENCES AVAILABLE WITH SEQLINK**  ANSWER IL OF 30 REGISTRY COPPRIGHT 2007 ACS on STN 735801-33-9 REGISTRY 735801-33-8 REGISTRY 735801-13-8 REGISTRY 735801-13-9 REGISTRY 735801-13-9 REGISTRY 735801-13-9 REGISTRY 735801-13-9 REGISTRY 735801-13-8 REGISTRY 73	!	CAPLUS
1 HSDAIPTDSY SRYRRQLAVR RYLAAVLGRR YRQRVRNR  1 HSDAIPTDSY SRYRRQLAVR RYLAAVLGRR YRQRVRNR  15 AT: 1-25  RELATED SEQUENCES AVAILABLE WITH SEQLINK**  ANSWER 11 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN 735801-33-9 REGISTRY  L-Argininamide, N-acetyl-L-hietidyl-L-arginyl-L-earyl-L-leucyl-L-arginyl-L-a	! ! !	location description
TEAT: 1-25  RELATED SEQUENCES AVAILABLE WITH SEQLINK**  ANSWER 11 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN  1-ASGINIAMANGA, N-acetyl-L-histidyl-L-d-aspartyl-L-seryl-L-tyrosyl-L-  135001-31-9 REGISTRY  1-ASGINIAL-L-reginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-  15001eucylglycyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-  15001eucylglycyl-L-rarginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-  1001ed  1001e	terminal mod.	C-terminal amide
RELATED SEQUENCES AVAILABLE WITH SEQLINK**  ANSWER 11 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 735801-33-9 REGISTRY L-Argininamide, N-acetyl-L-histidyl-L-asapattyl-L-aspattyl-L-tyrosyl-L- sioleucyl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L	н	
ANSWER 11 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 735801-33-9 REGISTRY L-Arginnamide, N-acetyl-L-histidyl-L-sarginyl-L-s		
ANSWER 11 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 735801-33-9 REGISTRY L-Argininamido, N-acctyl-L-histidyl-L-earyl-L-earyl-L-tyrosyl-L- isoleucyl-L-phenylalanyl-L-threonyl-L-arginyl-L-a		ES AVAILABLE WITH SEQLINK**
L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-d-spartyl-L-alanyl-L- isoleucyl-L-phenylalanyl-L-tyrosyl-L-asignyl-L-glutaminyl-L-tyrosyl-L- alanyl-L-varginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-arginyl-L-deucyl-L-alanyl-L-alanyl-L-arginyl-L-deucyl-L-alanyl-L-alanyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-alanyl-L-tyrosyl-L-arginyl-L-		REGISTRY COPYRIGHT 2007 ACS on
		<pre>.de, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L- phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L- nxyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L- -yl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-l- yl-L-arginyl-L-arginyl-(9CI) (CA INDEX NAME)</pre>
. १ १ में च . १ १ में १ १ १ १ १ १ १ १ १ १ १ १ १ १ १ १ १ १ १		
: 경험 : : : : : : : : : : : : : : : : : :	:	location
! ! ! ! 걸! ! ! ! ! ! ! ! ! ! ! ! ! ! !		
, 0 ; <del>1</del>	STN	CA, CAPLUS
1 H	!	location description
2 1 2 1 9		. C-terminal amide
rs refit	т	TIDSY SRYRRQLAVR RYLAAVLGRR
381	AT:	
		ES AVAILABLE WITH SEQLINK**
, E C		30 REGISTRY COPYRIGHT 2007 ACS on REGISTRY
L-teucytgiycyi-L-atginyi- (YL) (CA INDEA N 30 modified.		.de, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl- nyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L- rosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L- nyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucy
pe location d		(3C1) (CA 1MDBA
		TO

	200	
terminal mod.	Arg-30 - C-terminal amide	
LC STN Files: NTE modified	Ca, Caplus	
type	location desc	
terminal mod.	Arg-30 C-terminal amide	
-	HSDAIFTDSY SRYRRQLAVR RYLAAILGRR	
HITS AT: 1-25	HITS AT: 1-25 **RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
L8 ANSWER 13 OF	13 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN	
	kEGISTRY de, L-histic yl-L-threony rosyl-L-arginy	
	leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) 30 modified	
	location description	
terminal mod.	Arg-30 C-terminal amide	
LC STN Files: NTE modified	CA, CAPLUS	
type	location d	
terminal mod.	Arg-30 C-terminal amide	
SEQ 1 HSDAI	HSDAIFTDSY SRYRRQLAVR RYLAÀVLGRR	
HITS AT: 1-25		
**RELATED SEQUEN	**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
L8 ANSWER 14 OF 30	F 30 REGISTRY COPYRIGHT 2007 ACS on STN	
	phenylalanyl-L-threonyl-L- $\alpha$ -glutamyl-L-asparaginyl-L-tycosyl-L-tycosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-iarginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-GCI (CA INDEX NAME)	
		•
type	description description	
inal	-30 C-terminal	
LC STN Files:	CA, CAPLUS	
	7	

### 10/536880

NTE modified

Lype description
inal mod. Arg-30 - C-terminal a
SEQ 1 HSDAVFTENY TRLRRQLAVR RYLAAILGRR
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
L8 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RO 735801-25-9 REGISTRY
L-Argininamic valyl-L-pheny L-threonyl-L- alanyl-L-valy
isoleucyl-b-leucylglycyl-b-alginyl- (901) 21 30 TE modified
e description
d. His-1 . N-d. Arg-30 . C-
STN Files: CA, CAPLUS modified
pe location descri
3-30 0E-B
SEQ 1 HSDAVFTDNY TRLRRQLAVR RYLAAILGRR
HITS AT: 1-25 **RELATED SEQUENCES AVAILABLE WITH SEQLINK**
LB ANSWER 16 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 735801-24-8 REGISTRY
<pre>pnenylalanny1-L-Chrecony1-L-G-asparty1-L-asparaginy1-L-Tyrosy1-L- threony1-L-arginy1-L-arginy1-L-arginy1-L-glutaminy1-L-leucy1-L- alany1-L-valy1-L-arginy1-L-arginy1-L-tyrosy1-L-leucy1-L-alany1-L- isoleucy1-L-leucy1-L-arginy1- (9cI) (CA INDEX NAME)</pre>
SQL 30 WTE modified
type
inal mod. Arg-30 - C-ter
C STN Files: CA, CAPLUS TE modified

000000101	00000
location	description
0	ונוו
1 HSDAVFTDNY TRLRRQLAVR RYLAAILGR	
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
L8 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2007 ACS on RN 735327-72-7 REGISTRY	REGISTRY COPYRIGHT 2007 ACS on STN SISTRY 1histidol-1servl-1dasnartvl-1alanvl-1valvl-1
phenylalanyl-L-t arginyl-L-leucyl valyl-L-arginyl- L-leucylglycyl-HED	sparaginyl-L-tyrosyl-L-threonyl-L- -L-glutaminyl-L-leucyl-L-alanyl-L- L-leucyl-L-alanyl-L-isoleucyl- (INDEX NAME)
WO2004048401 SEQID: 24 cl JP2004315436 SEQID: 20 cl d	ed seguence.
location	scrip
nal mod. Arg-30 -	nal
Files: CA, CAPLUS, TOXCENTER, USPATF	1
ype	, ,
al mod. Arg-30	C-terminal
SEQ 1 HSDAVFTANY TRLRRQLAVR RYLAAILGRR	.RR
HITS AT: 1-25	
L8 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 702686-59-7 REGISTRY	. 2007 ACS on STN
CN L-Argininamide, L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-isoleucyl	α-aspartyl-L-alanyl-L-isoleucyl-
L-phenylalanyl-L-threonyl-L-α-aspartyl-L-Seryl-L-tyrosyl-L-seryl-L-arginyl-L	.yl-L-seryl-L-tyrosyl-L-seryl-L- -1-L-glutaminyl-L-leucyl-L-alanyl-L- L-leucyl-L-alanyl-L-alanyl-L-isoleucyl- tyrosyl-L-arginyl-L-glutaminyl-L- inyl- (9CI) (CA INDEX NAME)
1: PN: WO2004048401 SEQID: 31 claime 8 odified	ed sequence
e location	;
Arg-38	:
LC STW Files: CA, CAPLUS, TOXCENTER, USPATFUL NTE modified	USPATFULL

ype location descriptio	tion
terminal mod. Arg-38 - C-terminal amide	mide
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
SEQ 1 HSDAIFTDSY SRYRRQLAVR RYLAAILGRR YRQRVRNR	
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
L8 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 702686-58-6 REGISTRY	NL
	alanyl-L-isoleucyl-
-phenylalanyl-L-threonyl-L-d-aspartyl-L-seryl-L rginyl-L-trosyl-L-arginyl-L-arginyl-L-glutamin alyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-a eucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-L-arginyl	-tyrosyl-L-seryl-L- yl-L-leucyl-L-alanyl-L- lanyl-L-alanyl-L-alyl-L- inyl-L-glutaminyl-L- (CA INDEX NAME)
ER NAMES: 30: PN: WO2004048401 SEQID: 30 claimed pr 38 modified	
description	tion
inal mod. Arg-38 . C-t	mide
s: CA, CAPLUS, TOXCENTER, US	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ype location	tion
terminal mod. Arg-38 - C-terminal amide	mide
. SEQ 1 HSDAIFTDSY SRYRRQLAVR RYLAAVLGRR YRQRVRNR	
HITS AT: 1-25	
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	
L8 ANGWER 20 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 702686-57-5 REGISTRY	T.N
	partyl-L-alanyl-L-
- 0 0 >	-seryı-L-tyrosyı-L- utaminyl-L-leucyl-L- cyl-L-alanyl-L-alanyl-L- AME)
2	
s⊄r so NTE modified	
ype location d	tion
rminal mod. His-1 - N-acetyl rminal mod. Arg-30 - C-termina	mide

STN Files: CA, CAPLUS, TOXCENTER, USPATFULL modified
e location descr
terminal mod. Arg-30 - C-terminal amide
SEQ 1 HSDAIFTDSY SRYRRQLAVR RYLAAVLGRR  ==================================
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
L8 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 702686-56-4 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl- L-phenylalanyl-L-threonyl-L-a aspartyl-L-seryl-L-seryl-L-seryl-L- arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-laucyl-L-alanyl-L- valyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl- L-leucylglycyl-L-arginyl- (9C1) (CA INDEX NAME)
WO2004048401 SEQID: 28 claimed sequence d
location
1 mod. Arg-30 . C-terminal amid
STN Files: CA, CAPLUS, TOXCENTER, U
ype location location
terminal mod. Arg-30 - C-terminal amide
1 HSDAIFTDSY SRYRRQLAVR RYLAAILGRR
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
L8 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN RN 702666-55-3 REGISTRY
L-Argininamic L-Phenylalany arginyl-L-tyr valyl-L-argin
(301) 31D: 27
type location description

THE MODIFIES CA. CAPLUS, TOXCENTER, USPATFULL  WITE MODIFIES  LANGUAGE  THE MODIFIES  1 HEDALFTDEN SRYRROLAVE RYLAAVIGER  HITS AT: 1-25  ***RELIATED SEQUENCES AVAILABLE WITH SEQLINK***  CN 1-AGINIMAMICS. L'HASTIGNI-L-G-G-JULEMANJ-L-G-ABRATCHI-L-G-INNJ-L-VANJ-L- AGINIMAMICS. L'HASTIGNI-L-RECYJ-L-G-ABRATCHI-L-G-INNJ-L-VANJ-L- AGINIMAMICS. CN STR  CN 1-AGINIMAMICS. L'HASTIGNI-L-RECYJ-L-G-ABRATCHI-L-G-INNJ-L-VANJ-L- AGINIMAMICS. CN 1-AGINIMAMICS. L'HASTIGNI-L-G-BLANJ-L-AGINIMAN-L-AGI	STN Fi	CA, CAPLUS		USPATFULL
रकरना ने हैं है । करना रकरना ने ने हैं	inal mo	Arg-30	ion	
न्त्रा स्	inal mo	Arg-30		scription
्रास्ति । इ.स. १०० मा १०० म	.⊢ 		1	terminal
में हैं कि में कि में हैं हैं है			AVR RYLAAVLG	RR
हर्ष । जानी । । जानी । । । । । । ।	**RELATED SEQUE	ENCES AVAILABLE	WITH SEQLIN	K**
क्ष । शास्त्री । शास्त्री । क्ष	ANSWER 23 702686-53. L-Arginina phenylalar threonyl-L- alanyl-L-	OF 30 REGISTRY amide, L-histid nyl-L-threonyl- L-arginyl-L-leu valyl-L-arginyl L-arginyl	Y COPYRIGHT  yl-L-seryl-L  L-α-glutamyl  cyl-L-arginyl-	-0.007 ACS on STN -0aspartyl-L-alanyl-L-valyl-LL-asparaginyl-L-tyrosyl-Ll-arginyl-L-glutaminyl-L-leucyl-Iyyrosyl-L-leucyl-L-alanyl-G-T) (Gr. NIMPY NAME)
र्गे स्थापन स्थापन स्थापन	E C	02004048401 SEQ	ID: 22 claim	ed protein
म्बा म्थान्त्र हे ही 💢	1			scription
	inal mod.	4		nal amide
: 8 : 2 : 5 : 5	1	}	TOXCENTER,	
: 달 : '	; ; ; ;	T		description
· H	mod.	1 1		C-terminal
, ;; ;;		AVFTENY TRLRRQL		
8	. 03	S ENCES AVAILABLE	WITH SEQLIN	X* *
8	ANSWER 24	30		ő
25	702686-38. L-Arginine valy1-L-pf L-threonyl alany1-L-v	-2 REGISTRY amide, N-acetyl henylalanyl-L-t 1-L-arginyl-L-1 valyl-L-arginyl -L-leucylqlycyl	-L-histidyl- hreonyl-L-α- eucyl-L-argi -L-arginyl-L- -L-arginyl-L-	L-seryl-L-d-aspartyl-L-alanyl-L- aspartyl-L-asparaginyl-L-tyrosyl- nyl-L-arginyl-L-glutaminyl-L-leucyl -tyrosyl-L-leucyl-L-alanyl-L-alanyl (9CI) (CA INDEX NAME)
	8	02004048401 SEQ	ID: 14 claim	ed seguence
:	**RELATED SEQUE **RELATED SEQUE RN 70266-38 CN L-Arginine valy1-L-pt L-threonyl alany1-L-v isoleucy1-L-v SSOL 0 NTE modified	SENCES AVAILABLE OF 30 REGISTR -2 REGISTRY ammide, Vacetyl l-L-arginyl-L-1 valyl-L-arginyl-L-1 valyl-L-arginyl-L-1 L-1eucylglycyl L-1eucylglycyl D2004048401 SEQ	wITH SEQLIN Y COPYRIGHT -L-histidyl- hreenyl-L-argi -L-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginylL-arginyl-	***  1.2007 ACS on STN  L-Seryl-L-d-aspartyl-L-alanyl-L- aspartyl-L-tyrosyl- nyl-L-arginyl-L-glutaminyl-L-leucyl- ryrosyl-1-leucyl-L-alanyl-L-leucyl (9CI) (CA INDEX NAME)  ed sequence

### 

		: : : : :	!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!	1				$L$ -Argininamide, $L$ -hietidyl- $L$ -seryl- $L$ - $\alpha$ -aspartyl- $L$ -alanyl- $L$ -valyl- $L$ -phenylalanyl- $L$ -threonyl- $L$ - $\alpha$ -aspartyl- $L$ -arginyl- $L$ -tryrosyl- $L$ -threonyl- $L$ -arginyl- $L$ -arginyl- $L$ -arginyl- $L$ -arginyl- $L$ -arginyl- $L$ -aluanyl- $L$ -aluanyl- $L$ -alanyl- $L$ -alanyl- $L$ -tryrosyl- $L$ -alanyl- $L$ -alanyl- $L$ -arginyl- $L$ -arginyl- $L$ -tryrosyl- $L$ -laucyl- $L$ -alanyl- $L$ -arginyl-	мв)						1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			ANSWER 26 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 700368-96-3 REGISTRY L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L- phenylalanyl-L-threonyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L- threonyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L- alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L- valyl-L-valyl-L-arginyl-(9CI) (CA INDEX NAME) NAMES: RONGO 002004048401 SEOID: 26 claimed protein
	N-acetyl C-terminal amide	ULL	1 0	C-terminal amide			ACS on STN	L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L- phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L- threonyl-L-arginyl-L-laucyl-L-arginyl-L-arginyl-L-alaninyl-L-lau alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-alanyl-L-	(CA INDEX NAME)		description	C-terminal amide	ULL	rip	C-terminal amide			ANSWER 26 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 700368-96-3 REGISTRY L-Argininamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-arginyl-L-argaraginyl-L-tyrcosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-leucyl-L-arginyl-L-tyrcosyl-L-leucyl-L-valyl-L-arginyl-L-tyrcosyl-L-leucyl-L-arginyl-L-arginyl-L-tyrcosyl-L-leucyl-L-arginyl-L-arginyl-L-tyrcosyl-L-leucyl-L-arginyl-L-arginyl-L-tyrcosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrcosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrcosyl-L-leucyl-L-alanyl-L-arginyl-L-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-marginyl-g-margi
10/536880	:	CAPLUS, TOXCENTER, USPATFULL	:			SQLINK**	COPYRIGHT 2007 ACS on STN	ryl-L-α-asp artyl-L-asp rginyl-L-ar nyl-L-tyros	lyl- (9CI) claimed pro			C-te	ER, USPA	) 1 1 1 1 1 1 1 1 1		AAILGRR	EQLINK**	REGISTRY COPYRIGHT 2007 ACS on STN 15TRYhistidyl-L-seryl-L-d-aspartyl-L-al reonyl-L-d-aspartyl-L-asparaginyl-L- 1-L-leucyl-L-arginyl-L-raginyl-L-gl arginyl-L-arginyl-L-leucy rcyl-L-arginyl- (GA INDEX NAM
		JS, TOXCENT	: :	: . :	TRLRRQLAVR RYLAA	BLE WITH SI		tidyl-L-sel yl-L-α-aspe leucyl-L-ar yyl-L-argir	cyl-L-argin SEQID: 13 c		cation		JS, TOXCENT	cation		TRLRRQLAVR RYLAA mumenenses penses	BLE WITH SI	STRY COPY  tidyl*L-se; yl-L-αrapp  leucyl-L-argin L-arginyl-
	His-1 Arg-30	i .	location	Arg-30	1 HSDAVFTDNY TRLRRQLAVR RYLAAILGRR 00000000000000000000000000000000000	CES AVAILA	F 30 REGISTRY REGISTRY	ide, L-his 1-L-threon arginyl-L- lyl-L-argi	-leucylgly 004048401		location		CA, CAPL	; ;	Arg-30	1 HSDAVFTDNY TRLRRQLAVR RYLAAILGRR	CES AVAILA	ANSWER 26 OF 30 REGISTRY COPYRIGHT 2007 ACS 700368-96-3 REGISTRY L-Argininamide, L-histidyl-L-seryl-L-α-asparty phenylalamyl-L-threonyl-L-α-aspartyl-L-asparag threonyl-L-arginyl-L-leucyl-L-arginy
	terminal mod.	ı Fō		nal mod.		**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	ANSWER 25 OF 30 REGI 702686-37-1 REGISTRY	L-Argininam phenylalany threonyl-L- alanyl-L-va	isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA OTHER NAMES: CN 13: PN: WO2004048401 SEQID: 13 claimed protein	30 modified	:	terminal mod.	STN Files: modified	•	nal mod.		**RELATED SEQUENCES AVAILABLE WITH SEQLINK**	L8 ANSWER 26 OF 30 REGISTRY COPYRIGHT  RN 700368-96-3 REGISTRY  CN L-Argininamide, L-histidyl-L-seryl-L- phenylalanyl-L-treenyl-L-α-asparyl- threonyl-L-arginyl-L-leucyl-L-arginyl- alanyl-L-valyl-L-arginyl-L-arginyl-L- valyl-L-leucylglycyl-L-arginyl-L- valyl-L-leucylglycyl-L-arginyl-L- valyl-L-leucylglycyl-L-arginyl-R- OTHER NAMES:
	termi	μ	type	terminal	SEQ HITS AT:	* * REL	RN RN	Z Ü	OTHER	SOL	type	termi	ம		terminal	SEQ HITS AT:	**REL	LE RN CN CN OTHER

location description	nal amid	CAPLUS, TOXCENTER, USPATFULL	description	Arg-30 C-terminal amide	TRLRRQLAVR RYLAAVLGRR	1-25	F 30 REGISTRY COPYRIGHT 2007 ACS on STN	700368-90-7 REGISTRY L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-	phenylalanyl-L-threonyl-L-d-aspartyl-L-asparaginyl-L-tyrosyl-L- threonyl-L-arginyl-L-lencyl-L-arginyl-L-arginyl-L-glutaminyl-L-lencyl-L	alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-	<pre>1soleucy1-L-leucylglycy1-L-lysy1- (9CI) (CA INDEX NAME) NAMES:</pre>	004048401 SEQID: 21 claimed protein	SEQID:		Arg-30 - C-terminal amide	CA. CAPLUS, TOXCENTER, USPATFULL		location description	Arg-10 C-terminal amide	1 HSDAVFTDNY TRLRRQLAVR RYLAAILGKR	1-25	ANSWER 28 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN	REGISTRY	L-Argininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-valyl-L-	phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L- threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-	lyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-ala	alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L- isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)	lyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-ala -leucylglycyl- (9CI) (CA INDEX NAME) 004048401 SEOID: 20 claimed protein	alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-ala isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME) NAMES: 20: PN: WO2004048401 SEQID: 20 claimed protein 32: PN: JP2004315436 SEQID: 16 claimed sequence
type	minal m	LC STN Files: NTE modified		ninal	SEQ 1 HSDA	HITS AT: 1-25		RN 700368-90-7 CN L-Argininami	phenylalar	alanyl-L-v	1SOLEUCYL- OTHER NAMES:	CN 21: PN: WO2004048401	CN 33: PN: JE	type	terminal mod.	LC STN Files:	'	ec.	terminal mod.	SEQ 1 HSD#	==== HITS AT: 1-25			CN L-Arginine	phenylalar threonyl-I	alanyl-L-	alanyl-L-v isoleucyl-	ÆR	alanyl-L-v isoleucyl- OTHER NAMES: CN 20: PN: WC CN 32: PN: JI

15

### . 088965/01

TREGISTRY COPYRIGHT 2007 ACS on STRINGLAND ISCORDED IS CLERMINAL AND SERVINGLAND IN CONTRICT AND STRY COPYRIGHT 2007 ACS on SEQUENCE IS Claimed Sequence Incation	tion	amide		tion	amide			NI.	anvl-L-valvl-L-	-L.tyrosyl-L. glutaminyl-L.leucyl-L. cyl-L.alanyl-L.alanyl-L.		tion	mide			mide			TN	nyl-L-valyl-L- -L-tyrosyl-L- glutaminyl-L-leucyl-L- cyl-L-alanyl-L-alanyl-L-			
Arg-29  CA, CAPLUS, TOX  CA, CAPLUS, TOX  CA, CAPLUS, TOX  OF 10 REGISTRY C  OF 30 REGISTRY C  Arginyl-L-lacyl- alyl-L-threonyl-L-a- arginyl-L-lacyl- alyl-L-threonyl-L-a- arginyl-L-lacyl- alyl-L-arginyl-L-se  CA, CAPLUS, TOX  CA, CAPLUS, Location  Lys-29  CA, CAPLUS, COX  CA, CAPLUS, COX  CA, CAPLUS, Location  Lys-29  CA, CAPLUS, LOCATION		na 1	CENTER, USPATFULL	,		RYLAAILGR	10 to	OPYRIGHT 2007 ACS on S	ervl-L-α-aspartvl-L-al	aspartyl-L-asparaginyl L-arginyl-L-arginyl-L- rginyl-L-tyrosyl-L-leu CI) (CA INDEX NAME)	19 claimed protein 15 claimed sequence	descrip	- C-terminal a	:	descrip	C-terminal a	RYLAAILGK	0 0 0 0	OPYRIGHT 2007 ACS on S	ryl-L-α-aspartyl-L-ala aspartyl-L-asparaginyl L-arginyl-L-arginyl-L- rginyl-L-tyrosyl-L-leu	CA INDEX NAME)	18 claimed protein 14 claimed sequence	
ANSWER 29 ANSWER 30 ANSWER	location	Arg-29	STN Files: CA, CAPLUS, TOX modified		Arg-29	AVFTDNY TRLRRQLAVR		OF 30 REGISTRY C	-0 REGISTRY ide, L-histidyl-L-s	ıyl-L-threonyl-L-a- L-arginyl-L-leucyl- valyl-L-arginyl-L-a	02004048401 SEQID: P2004315436 SEQID:	location	Lys-29	STN Files: CA, CAPLUS, TOX modified	'	; ;	AVFTDNY TRLRRQLAVR	1-25	OF 30 REGISTRY C	Glycinamide, L-histidyl-L-se Glycinamide, L-histidyl-L-a- phenylalanyl-L-threonyl-L-a- threonyl-L-arginyl-L-leucyl- alanyl-L-valyl-L-arginyl-L-a	-L-leucyl- (9CI) (	02004048401 SEQID: P2004315436 SEQID:	

	22
location description	terminal mode of the 20
C-terminal ami	THE STATE OF THE S
CA, CAPLUS, TOXCENTER, USPATFULL	LC SIN Fles: CA, CAPLUS, TOXCENTER, USPATFULL
description	type location description
	terminal mod. Gly-28 - C-terminal amide
AFERTONY TRLERROLAUR RYLAAILGR	SEQ 1 HSDAVFTDNY TRIRRQLAVR RYLAAILG
OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 0 REGISTRY 0 REGISTRY 10 REGISTRY 10 REGISTRY 11 L- seryl-L-α-sapartyl-L-alanyl-L-valyl-L- 11 - thretidyl-L-aspartyl-L-asparadinyl-L-tyrosyl-L- 12 - arginyl-L-larginyl-L-arginyl-L-arginyl-L-leucyl-L- 13 - 14 - L-arginyl-L-tyrosyl-L-leucyl-L- 14 - L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L- 15 - L-leucyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L- 16 - L-Leucyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L- 17 - L-Leucyl-L-tyrosyl-L-tyrosyl-L- 18 - L-Leucyl-L-tyrosyl-L-tyrosyl-L- 19 - L-Leucyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L- 19 - L-Leucyl-L-tyrosyl-L-t	
2004048401 SEQID: 19 claimed protein 2004315436 SEQID: 15 claimed sequence	
location descript	
Lys-29 - C-terminal amide	
CA, CAPLUS, TOXCENTER, USPATFULL	
1 13	
Lys-29 - C-terminal amide	
VFTDNY TRLRRQLAVR RYLAAILGK	
OF 30 REGISTRY COPYRIGHT 2007 ACS on STN 8 REGISTRY	
2004048401 SEQID: 18 claimed protein	

FILE 'CAPLUS' ENTERED AT 12:21:11 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STIN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS) -> file caplus

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1998), unless otherwise indicated in the original publications. of this information, without the prior written consent of CAS, is the copyrighted intellectual property of the strictly prohibited CA Lexicon is

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6 FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply They are available for your review at:

ONOUE S?/AU L19 AND (L20 OR L21) L20 AND L21 MATSUMOTO A?/AU (L22 OR L23) ENDO K?/AU http://www.cas.org/infopolicy.html PLU=ON PLU=ON PLU=ON PLU=ON PLU=ON 2952 SEA PILE=CAPLUS ABB=ON F 4255 SEA FILE=CAPLUS ABB=ON F 118 SEA FILE=CAPLUS ABB=ON F 16 SEA PILE=CAPLUS ABB=ON F 23 SEA PILE=CAPLUS ABB=ON F 23 SEA PILE=CAPLUS ABB=ON F 24 SEA PILE=CAPLUS ABB=ON F 25 SEA PILE=CAPLUS ABB—ON F 25 SEA PILE=CAPUS ABB—ON F 25 SEA P 1.24 stat que 1.20 1.21 1.22 1.23 1.23

d stat que L25

AMI?/NTE HSDA[IV]FT[DEA][SND]Y[ST]R[YL L6 AND L3 23 PLU=ON PLU=ON PLU=ON FILE=CAPLUS ABB=ON PLU=ON 113096 SEA FILE=REGISTRY ABB=ON 54 SEA FILE=REGISTRY ABB=ON ]RRQLAVRRYLAA/SQSP 30 SEA FILE=REGISTRY ABB=ON 4 SEA FILE=CAPLUS ABB=ON P ខ្លួ E E 3

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT

Structure attributes must be viewed using STN Express query preparation: Uploading L10.str

10/536880

96

95

94

24-37 32-51 6-23 7-26 7-27 8-28 71-73 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62 56-57 20-75 21-46 22-38 22-101 23-24 23-76 31-98 65-68 66-68 67-68 69-70 70-71 71-72 86-87 87-88 88-89 88-90 91-104 94-97 35-100 36-53 36-101 38-39 38-54 39-40 39-41 55-56 30-50 31-32 29-104 29-30 28-49 96-56 18-74 19-45 20-21 27-84 64-65 84-85 85-86 94-96 92-93 93-94 27-28 63-64 2-14 3-15 9-31 10-32 26-48 62-63 81-83 16-69 chain bonds : 35-36 16-17 60-61 78-79 81-82 91-92 18-19 25-37 25-77 33-99 ring bonds : ring nodes 91 92 93 2-13 58-61 91-95 15-43 25-26 34-52 59-61 80-81 17-44 24-47 1-12

60-61 33-34 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28 13 11-34 11-35 12-13 12-55 13-42 14-15 14-62 79-80 80-81 22-101 23-24 23-76 32-51 59-61 31-32 58-61 78-79 29-104 30-50 57-58 77-78 56-57 22-38 71-73 55-56 71-72 21-46 29-30 39-41 20-75 28-49 10-07 39-40 20-21 27-84 02-69 2-14 3-15 3-16 4-9-31 10-32 10-33 38-54 19-45 27-28 67-68 36-101 38-39 18-74 26-48 89-99 16-69 exact/norm bonds 16-17 25-77 35-36 65-68 18-19 25-37 63-64 2-13 9-30 15-43 34-52 1-12 24-47 62-63

17

<u>«</u>

91-104 94-97

88-90

88-89

87-88

86-87

81-83

91-95 91-92 92-93 93-94 94-96 95-96 33-99 35-100 normalized bonds exact bonds :

Match level

92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:CLASS 98:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 9:CLASS 9:CLASS S 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 27: CLASS 37:CLASS 47:CLASS 87:CLASS 82:CLASS 83:CLASS 84:CLASS 85:CLASS 86:CLASS 25:CLASS 26:CLASS 66:CLASS 76:CLASS 46:CLASS 36:CLASS 56:CLASS 45:CLASS 64:CLASS 65:CLASS 35:CLASS 75:CLASS 55 : CLASS 23:CLASS 24:CLASS 34:CLASS 44:CLASS 74:CLASS 54:CLASS 62:CLASS 63:CLASS 33:CLASS 43:CLASS 72:CLASS 73:CLASS 53:CLASS 101:CLASS 104:CLASS 22:CLASS 42:CLASS 32:CLASS 52:CLASS 11:CLASS 21:CLASS 29:CLASS 41:CLASS 49:CLASS 61:CLASS 69:CLASS 81:CLASS 89:CLASS 31:CLASS 71:CLASS 19:CLASS 39:CLASS 51:CLASS 59:CLASS 79:CLASS 1:CLASS 2 10:CLASS 100:CLASS 18:CLASS 20:CLASS 28:CLASS 30:CLASS 38:CLASS 40:CLASS 48:CLASS 50:CLASS 50:CLASS 60:CLASS 70:CLASS 70:CLASS 78:CLASS 78:CLASS 90:CLASS

MATSUMOTO A?/AU 11 SEA FILE-REGISTRY SSS FUL L10
9 SEA FILE-CAPLUS ABB-ON PLU-ON
2952 SEA FILE-CAPLUS ABB-ON PLU-ON
4255 SEA FILE-CAPLUS ABB-ON PLU-ON
118 SEA FILE-CAPLUS ABB-ON PLU-ON
3 SEA FILE-CAPLUS ABB-ON PLU-ON
0 N L9) L15 L16 L19 L20 L20 L21

ONOUE S?/AU (L19 OR L20 OR L21) AND (L16 ENDO K?/AU PLU=ON PLU=ON PLU=ON PLU=ON

=> \$ L24-L25

25 (L24 OR L25)

=> file medline embase biosis FILE 'MEDLINE' ENTERED AT 12:21:41 ON 30 JAN 2007

FILE 'EMBASE' ENTERED AT 12:21:41 ON 30 JAN 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:21:41 ON 30 JAN 2007 Copyright (c) 2007 The Thomson Corporation

=> d stat que L30

MATSUMOTO A?/AU PLU=ON PLU=ON PLU=ON PLU=ON PLU=ON [130 [121 [122 [123 [124

ENDO K?/AU ONOUE S?/AU L19 AND (L20 OR L21) L20 AND L21 (L22 OR L23) 2952 SEA FILE-CAPLUS ABB-ON P 4255 SEA FILE-CAPLUS ABB-ON P 118 SEA FILE-CAPLUS ABB-ON P 15 SEA FILE-CAPLUS ABB-ON P 16 SEA FILE-CAPLUS ABB-ON P 23 SEA FILE-CAPLUS ABB-ON P 42 SEA L24

10/536880

FILE 'TOXCENTER' ENTERED AT 12:21:53 ON 30 JAN 2007 COPYRIGHT (C) 2007 ACS => file toxcenter

FILE COVERS 1907 TO 23 Jan 2007 (20070123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MeSH terms.and See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2007 vocabulary.

=> d stat que L29

PLU-GON MATSUMOTO A?/AU
PLU-GON ENDO K?/AU
PLU-GON ONOUE S?/AU
PLU-GON L19 AND (L20 OR L
PLU-GON L20 AND L21 2952 SEA FILE=CAPLUS ABB=ON PLU=ON MATSUMOTO A?/AU 4255 SEA FILE=CAPLUS ABB=ON PLU=ON ENDO K?/AU 118 SEA FILE=CAPLUS ABB=ON PLU=ON ONOUG S?/AU 13 SEA FILE=CAPLUS ABB=ON PLU=ON L19 AND (L20 OR 16 SEA FILE=CAPLUS ABB=ON PLU=ON L20 AND L21 20 SEA FILE=TOXCENTER ABB=ON PLU=ON (L22 OR L23)

L19 AND (L20 OR L21) L20 AND L21

=> dup rem L32 L30 L29 FILE 'GAPLOS' ENTREED AT 12:22:17 ON 30 JAN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERNS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:22:17 ON 30 JAN 2007

FILE 'EMBASE' ENTERED AT 12:22:17 ON 30 JAN 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:22:17 ON 30 JAN 2007 Copyright (c) 2007 The Thomson Corporation FILE 'TOXCENTER' ENTERED AT 12:22:17 ON 30 JAN 2007

COPYRIGHT (C) 2007 ACS

PROCESSING COMPLETED FOR L32 PROCESSING COMPLETED FOR L30 PROCESSING COMPLETED FOR L29

32 DUP REM L32 L30 L29 (SS DUPLICATES REMOVED) ANSWERS '1-25' PROM FILE CAPLUS ANSWER '26' FROM FILE MEDLINE ANSWERS '27-32' FROM FILE BIOSIS

=> d ibib abs hitind hitstr L33 1-25; d iall L33 26-32

L33 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1 2006:485110 CAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

145:109921 Development of dry powder inhalation system of nc vasoactive intestinal peptide (VIP) analogue for

novel

pulmonary administration Ohmori, Yuki; Onoue, Satomi; Endo,

6

AUTHOR (S):

Kosuke; Matsumoto, Asami; Uchida,

limited by its rapid degradation in addition to the systemic adverse effects due to the wide distribution of VIP receptors. To overcome these problems, we succeeded to synthesize a novel VIP derivative of VIP, [R15, 20, 21, 117] -VIP-GRR (IK115312), and to prepare its dry powder for the topical administration to the lung. The physicochem. properties of dry powder were evaluated by laser diffraction and cascade impactor. The laser diffraction anal. indicated resp., and the air flow at the pressure of 0.15 MPa or higher resulted in the high dispersion and significant separation of fine particle containing peptide from the carrier mol. The cascade impactor anal. clearly showed the high maximal number of binding sites (Bmax) for [1251] VIP in anterior and posterior emission of dry powder from capsule and the deposition of peptide on stages 3 of the cascade impactor. The intratracheal administration of dry powder inhaler (DPI) of VIP or IK312532 brought about a significant decrease of Thus, the administration of VIP may be useful for the therapy of diseases. However, the therapeutic application of VIP is largely receptors. This effect by IX312532-DPI compared with VIP-DPI lasted for a longer period. Thus, IX312532-DPI may be a pharmacol. useful drug delivery system for the VIP therapy of pulmonary diseases such as asthma. that the carrier and fine particles had median diameter of 65.6 and 4.5 µm, smooth muscle which is mediated through interaction with VIP receptors. The deficiency of VIP in the airways has been implicated in the pathogenesis of Vasoactive intestinal peptide (VIP) exerts a relaxing action on tracheal lobes of rat right lung, suggesting a significant occupancy of lung VIP Department of Pharmacokinetics and Pharmacodynamics and COE Program in the 21st Century, School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka, 422-8526, Japan Life Sciences (2006), 79(2), 138-143 CODEN: LIFSAK, ISSN: 0024-3205 Shinya; Yamada, Shizuo Elsevier B.V. Journal English pulmonary diseases. CORPORATE SOURCE: DOCUMENT TYPE: LANGUAGE: PUBLISHER:

THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

63-5 (Pharmaceuticals)

CC 63-5 (Pharma REFERENCE COUNT:

Erythritol-based dry powder of glucagon for pulmonary Pharmaceutical Division, Ito Life Sciences Inc., Moriya, Ibaraki, 302-0104, Japan International Journal of Pharmaceutics (2005), US COPYRIGHT 2007 ACS on STN DUPLICATE 2 2005:48083 CAPLUS Full-text Endo, Kosuke; Amikawa, Satoko; Matsumoto, Asami; Sahashi, Norio; Onoue, 290(1-2), 63-71 administration 143:83291 Satomi L33 ANSWER 2 OF 32 CAPLUS ACCESSION NUMBER: 200 CORPORATE SOURCE: DOCUMENT NUMBER: AUTHOR (S): SOURCE: TITLE:

Glucagon, a key regulatory element of glycogen metabolism, is known to be effective in the clin. treatment of hypoglycemia and the maintenance of normal circulating glucose levels in patients with total pancreatectomy, however the clin. use of this gut hormone has been restricted to parenteral administration. In this investigation, we prepared dry powder dosage forms of glucagon, which were formulated by mixing micronized glucagon particles and English LANGUAGE: ΑB

CODEN: IJPHDE, ISSN: 0378-5173

Elsevier B.V.

Journal

DOCUMENT TYPE:

PUBLISHER:

10/536880

ō excipients with larger carrier particles. To achieve alveolar deposition for subsequent systemic absorption, a dry powder inhalant (DPI) of glucagon was laser diffraction anal. The use of erythritol as both excipient and carrier in DPI of glucagon resulted in high and reproducible flowability and dispersibility of the powder mixts., and therefore it provided a low dosing ( the active substances. Distinct transpulmonary absorption of glucagon was confirmed after intratracheal administration of the glucagon dry powder to anesthetized rats, as evidenced by the increase in the blood glucagon and blood sugar levels. These results suggested the usefulness of an erythritol-based powder form of glucagon for systemic administration. size-reduced to a mass median diameter between 1 and 6 µm, as measured by 63-5 (Pharmaceuticals)

Section cross-reference(s): 2
REFERENCE COUNT: 30 THER ပ္ပ

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 30

4 1, AM, AZ, 1, DK, EE, 2, SI, SK, 1, SN, TD, 20031121 SE, MC, PT, HU, SK 3 8 5 8 8 20031121 Peptides and medicinal compositions containing the 20031121 20031121 20031121 20021127 20050527 W 20031121 ð ZW. DE, ZM, . 32 Ä, COPYRIGHT 2007 ACS on STN DUPLICATE 3 MX, SK, ZA, ZM, CZ, , MG, MK, MM, MW, 1, SC, SD, SE, SG, 3, UZ, VC, VM, VU, 3, L, SZ, TZ, UG, 7, BE, BG, CH, CY, 1, LU, MC, NL, PT, 1, GN, GQ, GM, ML, 1, GN, GQ, CM, ML, 1, QN, CQ, CM, ML, 1, QN, C GB, GR, IT, LI, LU, CY, AL, TR, BG, CZ, CN 2003-80107764 US 2005-536880 KG, W NO 2003-JP14924 JP 2002-344523 WO 2003-JP14924 APPLICATION NO. 2004:467910 CAPLUS Full-text Onoue, Satomi; Endo, Kousuke; Japan PCT Int. Appl., 73 pp. Itoham Foods Inc., Matsumoto, Asami DK, III, MA, WZ, MZ, CM, 20040610 20060208 20040610 ĀŘ, 20061207 20040618 20050907 CODEN: PIXXD2 ES, AU, Ë, Ρ, Υ. UA, 80, 를 된 , 141:33832 Japanese AT, Ķ, CZ, Eŭ, TZ, LLS, RU, GR, FI, Patent KIND DE, LV, A A A1 CAPLUS GG, HR, E 1 E 1 MD, GB, CF, A1 를 유. 환. ë 5 ΚΖ, FR, FAMILY ACC. NUM. COUNT: PRIORITY APPLN. INFO.: BY, KG, ES, FI, TR, BF, AE, AG, CN, CO, GE, GH, LK, LR, NZ, OM, TM, TN, BW, GH, BE, L33 ANSWER 3 OF 32 ACCESSION NUMBER: IE, SI, CA 2507616 AU 2003284428 EP 1571155 PATENT ASSIGNEE(S): PATENT INFORMATION: WO 2004048401 2006276384 DOCUMENT NUMBER: R: AT, CN 1732182 US 20062763 PATENT NO. DOCUMENT TYPE: INVENTOR (S): SOURCE: TITLE:

tautomerization of peptide derived from a PACAP peptide or a VIP peptide or a pharmaceutically Disclosed is a medicinal composition containing, as the active ingredient, acceptable salt thereof. Thus, a PACAP/VIP derivative the tautomerization which in the state of a solution is inhibited and thus which can be clin. neurodegenerative diseases, erectile dysfunction and bronchial asthma. These peptides are efficacious in ameliorating symptoms of diseases such as regressive employed over a long period of time is provided. acceptable salt thereof. AB

peptide His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg- Arg-Gln-Leu-Ala-Val-Arg-Arg-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Gly-Arg-Arg-NH2 (I) was prepared, and its stability in water with various pH was tested. An inhalant powder

ü

CO7K014-00 AGIXO38-16, AGIPD01-12, AGIPD07-02, AGIPD09-00, AGIPD09-10, AGIPD11-08, AGIPD13-12, AGIPD15-10, AGIPD17-14, AGIPD25-00, AGIPO25-28, AGIPD27-02 containing I with erythritol carrier was formulated. ICM C07K014-00 ICS A61K038-16; A61P001-12; A61P007-02; A61P009-00;

127317-03-7P 700368-81-6P 1-12 (Pharmacology) Section cross-reference(s): 63 ပ္ပ H

40077-57-4P, Vagoactive intestinal octacosapeptide (swine) 1134582-08-4P 475081-13-TP 700368-75-9P 700368-79-2P 700368-83-8P 700368-83-8P 700368-87-P 700368-99-7P 700368-99-9P 700368-94-1P 700368-95-3P 700369-00-2P 700369-02-4P 702686-30-4P 702686-36-0P 702686-36-0P 702686-37-1P 702686-38-2P

702686-31-5P

702686-52-0P 702686-53-1P 700368-98-5P 700369-00-2P 700369-00 702686-33-7P 702686-36-0P 702686-37-1 702686-42-8P 702686-49-5P 702686-57 702886-55-3P 702886-56-4P 702686-57-5P 702686-58-6P 702686-59-7P 735327-72-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptides containing PACAP/VIP derivs. and medicinal compns.) 700368-83-8P 700368-85-0P 700368-87-2P 700368-90-7P 700368-95-3P 702866-37-1P 702866-35-2P 702686-35-3P 702686-55-4P 702686-57-5P 702686-58-6P 7035327-72-7P

H

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(peptides containing PACAP/VIP derivs. and medicinal compns.) (Preparation); USES (Uses)

CAPLUS

700368-83-8

S S

alanyl L.valyl L.arginyl L.arginyl L.trosyl L.leucyl L.alanyl L.alanyl L. alanyl L. isoleucyl L.leucyl (9CI) (CA INDEX NAME) phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-Glycinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-

Absolute stereochemistry

PAGE 1-A

10/536880

PAGE 1-C

PAGE 1-E

Z Z

$$\label{eq:conversion} \begin{split} phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-\\ threonyl-L-arginyl-L-gleucyl-L-arginyl-L-glutaminyl-L-leucyl-L-\\ alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucyl-L-glylycyl- (9CI) (CA INDEX NAME) \end{split}$$
L-Lysinamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-valyl-L-

Absolute stereochemistry.

PAGE 1-C

### 700368-87-2 CAPLUS

L-Argininamide, L-histidyl-L-Seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-teucyl-L-arginyl-L-tyrosyl-L-teucyl-L-toucyl-L-C Z

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

C RN

10/536880

700168-90-7 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-Lthreonyl-L-arginyl-L-leucyl-L-arginyl-L-targinyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-teucyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-tyrosyl-L-teucyl-L-alanyl-L-tylogy

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-E

10/536880

700368-96-3 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-Lthreonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-Lalanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-anylyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucyl-L-arginy Z Z

Absolute stereochemistry.

702686-37-1 CAPLUS

phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-S S

3

(CA INDEX NAME) isoleucyl-L-leucylglycyl-L-arginyl- (9CI)

### STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CAPLUS 702686-38-2 RN

valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-trireonyl-L-trireonyl-L-trireonyl-L-trireonyl-L-arginyl-L-gultaninyl-L-leucyl-L-arginyl-L-gultaninyl-L-leucyl-L-alanyl-L-trireonyl-L-targinyl-L-trireonyl-L-leucyl-L-alanyl-L-tsi L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-Lü

# STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

702686-53-1 CAPLUS \* % X X

alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-L-Argininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-àlanyl-L-valyl-L $phenylalanyl-L-threonyl-L-\alpha-glutamyl-L-asparaginyl-L-tyrosyl-L-$ 

### STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* \* \* N

702686-55-3 CAPLUS

L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-allanyl-L-allanyl-L-ulanylyl-L-arginyl-L-arginyl-L-allanyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl-Z

# STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

702686-56-4 CAPLUS \* KR \*

arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) L-Argininamide, L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-

## STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-702686-57-5 CAPLUS RN \*

alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L $isoleucyl-L-phenylalanyl-L-threonyl-L-\alpha-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-glutamin$ (CA INDEX NAME) valy1-L-leucylglycyl-L-arginyl- (9CI)

### STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* \* % %

702686-58-6 CAPLUS

valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-Larginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucylleucy1g1ycy1-L-arginy1-L-arginy1-L-tyrosy1-L-arginy1-L-glutaminy1-Larginy1-L-valy1-L-arginy1-L-asparaginy1 (9C1) (CA INDEX NAME)  $L\text{-phenylalanyl-}L\text{-threonyl-}L\text{-}\alpha\text{-aspartyl-}L\text{-seryl-}L\text{-tyrosyl-}L\text{-seryl-}L\text{-}$ 

# STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 702686-59-7 CAPLUS

702686-59-7 \* % % %

valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L- $L-Argininamide,\ L-histidyl-L-seryl-L-\alpha-aspartyl-L-alanyl-L-isoleucyl-L-alanyl-$ 

10/536880

(CA INDEX NAME) arginyl-L-valyl-L-arginyl-L-asparaginyl- (9CI)

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 735327-72-7 CAPLUS

: 2 Z Z

L-Argininamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-threonyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-B

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar Health Science Division, Itoham Foods Inc., Ibaraki, European Journal of Biochemistry (2004), 271(9), Onoue, Satomi; Ohmori, Yuki; Endo, Kosuke; Yamada, Shizuo; Kimura, Ryohei; Yajima, CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4 CODEN: EJBCAI; ISSN: 0014-2956 Blackwell Publishing Ltd. 2004:371854 CAPLUS Full-text 140:418294 1757-1767 L2 cells Takehiko 18 L33 ANSWER 4 OF 32 CACESION NUMBER:
DOCUMENT NUMBER: CORPORATE SOURCE: REFERENCE COUNT: AUTHOR (S): PUBLISHER: SOURCE:

Journal English DOCUMENT TYPE: LANGUAGE ΑB

vitro study of rat lung alveolar L2 cells, digatette smoke extract (CSE) induced apoptoric cell death. Exposure of L2 cells to CSE at a concentration of 0.25t resulted in a 50t increase of caspase-3 and matrix metalloproteinase (MMP).activities. Specific inhibitors for caspases and MMPs attenuated the cytocoxicity of CSE. RT-PCR amplification identified VPAC2 receptors in L2 cells. A radioligand-binding assay with 1251-labeled vasoactive intestinal peptide (VIP) found high affainty and saturable 1251-labeled VIP-binding sites in L2 cells. VIP and pituitary adenylate cyclase-activating polypeptide (PACAP27) were approx. equipotent for both VIP receptor binding and stimulation of CAMP production in L2 cells. Both neuropeptides, at concns. higher than 10-13 M, produced a concentration-dependent inhibition of CSE-In an in PACAP27 significantly attenuate the cytotoxicity of CSE through the activation of VPAC2 receptor, and the protective effect of VIP may partly be the result of a reduction in the CSE-induced stimulation of MMPs and caspases. associated with cigarette smoking. A central feature of chronic obstructive pulmonary disease is inflammation coexisting with an abnormal induced cell death in L2 cells. VIP, at 10-7 M, reduced CSE-stimulated MMP activity and caspase-3 activation. The present study has shown that VIP and Chronic obstructive pulmonary disease is a major clin. disorder usually protease/antiprotease balance, leading to apoptosis and elastolysis.

2-6 (Mammalian Hormones) ပ္ပ

Section cross-reference(s): 4

: 4 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 20 REFERENCE COUNT:

CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5 2004:35149 CAPLUS Full-text ANSWER 5 OF 32 ACCESSION NUMBER:

140:297670

DOCUMENT NUMBER:

Structure activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with

arginine

Shizuo; Kimura, Ryohei; Yajima, Onoue, Satomi; Ohmori, Yuki; Matsumoto, Asami; Yamada, Shizuo; Kimura, Ryohei; Takehiko; Kashimoto, Kazuhisa

Health Science Division, Itoham Foods Inc., Moriya,

CORPORATE SOURCE:

Ibaraki, 302-0104, Japan Life Sciences (2004), 74(12), 1465-1477 CODEN: LIFSAK; ISSN: 0024-3205

Elsevier Science Inc. Journal

PUBLISHER:

English DOCUMENT TYPE: LANGUAGE:

binding activity even at high concns., suggesting the requisite of 23 amino acid residues as the minimal essential sequence for the conservation of VIP receptor binding activity. The chemical modification of VIP(1-23) generated a potent analogi [Argl5, 20, 21, Leul7]-VIP(1-23), that displayed a 22-fold higher receptor binding activity and 1.6-fold more potent relaxation of mouse stomach than VIP(1-23) did. In conclusion, it was shown that [Argl5, 20, 21, In order to develop potent shortened analogs of vasoactive intestinal peptide (VIP), the structure-activity relationship of C-terminally truncated analogs of VIP was investigated by examining the binding activity to rat lung VIP receptors and relaxation of smooth muscle in isolated mouse stomach. VIPIL-27) showed VIP receptor binding activity comparable to that of VIP but the activity of VIP(1-26) was reduced to one-third of VIP. The receptor binding activity of VIP(1-26) to VIP(1-23) was reduced in proportion to the decrease in amino acid residues. There was a significant correlation between the number of amino acid residues and VIP receptor binding activities of VIP and its C-terminally truncated analogs. VIP(1-22) and VIP(1-21) exhibited little

Leul7]-VIP(1-21) could be a relatively potent and stable agonist of VIP receptors. The present study has provided further insight into the structure-activity relationship of VIP to generate novel shortened VIP analogs having a high affinity to VIP receptors and potent pharmacol. activity.

(Mammalian Hormones) CC 2-2 (Mammal REFERENCE COUNT:

THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 6 2004:78836 CAPLUS Full-text L33 ANSWER 6 OF 32 ACCESSION NUMBER:

140:264668 DOCUMENT NUMBER:

 $\alpha\textsc{-Helical}$  structure in the C-terminus of vasoactive intestinal peptide: functional and Onoue, Satomi; Matsumoto, Asami; structural consequences

Kimura, Ryohei; Yajima, Takehiko; Nagano, Yumiko; Ohshima, Keiichi; Ohmori, Yuki; Yamada, Shizuo;

Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., Moriya,

CORPORATE SOURCE:

SOURCE:

AUTHOR (S):

Ibaraki, 302-0104, Japan

European Journal of Pharmacology (2004), 485(1-3), CODEN: EJPHAZ; ISSN: 0014-2999 307-316

Elsevier Science B.V.

English PUBLISHER: LANGUAGE:

The conformational properties of vasoactive intestinal peptide (VIP) include structure. The authors have previously observed that the N-terminal random the N-terminal randomized structure and the C-terminal long  $\alpha\text{-helical}$ AB

each of which corresponds to 14 amino acid residues. VIP-(1-26) was 10% and threefold less potent in relaxant and binding activities, resp., compared with between their  $\alpha$ -helical contents and their biol. activities including relaxant effects on murine stomach and receptor-binding activities. VIP and VIP-(1-27) chain, and N-terminus of the  $\alpha$ -helical region, and evaluated the relationship showed equipotent biol. activities with 48% and 50%  $\alpha$ -helical content, resp., clarify how the formation of the  $\alpha$ -helix plays a role in its biol. functions, the authors chemical synthesized VIP analogs modified at the C-terminus, mid-VIP, and its 49%  $\alpha$ -helical content resulted in 13 residues involved in the  $\alpha$ coil structure plays a crucial role in the receptor-selectivity. Here, to

helix. Further truncation from 25 to 21 resulted in decrease in the  $\alpha\text{-helical}$  content from 41 to 25, corresponding residues from 11 to 6, the relaxant activity from 72% to 4%, and the affinity to the membrane from 60-fold to over 104-fold less potency. In addition, disruption of the mid-chain and the Nterminus in the  $\alpha$ -helical stretch by oxidation of Met17 and deletion of Thr11  $\alpha$ -helical structure forming in 14 amino acid residues between position 10 and 23 in VIP is essential to its biol. functions and the C-terminal amino acid residues between position 24 and 27 are requisite for this  $\alpha$ -helical also inhibited biol. activities. These findings suggest that the presence of

2-2 (Mammalian Hormones) 53 CC 2-2 (Mammali REFERENCE COUNT: formation.

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

COPYRIGHT 2007 ACS on STN DUPLICATE 7 2004:917676 CAPLUS <u>Full-text</u> 141:389080 CAPLUS L33 ANSWER 7 OF 32 ACCESSION NUMBER:

DOCUMENT NUMBER:

characteristics of a novel VIP analogue, [R15, 20, 21, Pharmacological effects and lung-binding

Shuji, Kimura, Ryohei; Ohmori, Yuki; Maruyama, Shuji; K: Onoue, Satomi; Matsumoto, Asami; L17)-VIP-GRR (IK312532) AUTHOR (S):

Kosuke; Iwanaga, Toshihiko; Kashimoto, Kazuhisa; Yamada, Shizuo

CORPORATE SOURCE:

School of Pharmaceutical Sciences, Department of Biopharmaceutical Sciences and COE Program in the 21st Century, University of Shizuoka, Shizuoka, 422-8526,

Japan

Regulatory Peptides (2004), 123(1-3), 201-207 CODEN: REPPDY; ISSN: 0167-0115 Elsevier B.V. Journal DOCUMENT TYPE: PUBLISHER:

English

LANGUAGE:

SOURCE:

A novel VIP derivative, [R15, 20, 21, L17]-VIP-GRR (IK 312532), relaxed potently the carbachol-induced contraction of guinea pig isolated trachea with longer duration than that induced by VIP. IK 312532 competed with [1251]VIP There was considerable decrease in specific [125]VIP binding in each lobe of right and left lung 0.5 h after the intratracheal administration of IK 312532 (50 µg/rat) as dry powder inhaler (DPI). Rosenthal anal. revealed that the administration of IX 312532 (50 and 100 µg/rat)-DPI brought about a significant decrease of maximal number of binding sites (Bmax) for specific [1251]VIP binding in anterior and posterior lobes of rat right lung, for the binding sites in the rat lung in a concentration-dependent manner.

lung VIP receptors as well as a suppression of the antigen-evoked infiltration of granulocytes in the bronchiolar mucosa. Thus, the formulation of IK 312532 as DPI may be a pharmacol. useful drug delivery system for the therapy of pulmonary diseases such as asthma. μg/rat)-DPI. In conclusion, the present study has shown that IK 312532 exhibits long-lasting relaxation of tracheal smooth muscles and that the intratracheal administration of this peptide exerts a significant occupancy of suggesting a significant occupancy of lung VIP receptors. This effect by IK 312532 in the posterior lobe of the right lung was dose-dependent and lasted until at least 2 h after the intratracheal administration. Furthermore, the antigen-evoked infiltration of granulocytes in the rat bronchiolar mucosa was markedly suppressed by the intratracheal administration of IK 312532 (50

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 2-6 (Mammalian Hormones) CC 2-6 (Mammal: REFERENCE COUNT:

34

L33 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 8 ACCESSION NUMBER: 2004:917675 CAPLUS <u>Full-text</u>

141:389079 Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette DOCUMENT NUMBER: TITLE:

Ohmori, Yuki; Yamada, Shizuo; Kimura, Ryohei; Yajima, Onoue, Satomi; Endo, Kosuke; smoke AUTHOR (S):

Health Science Division, Itoham Foods Inc., Moriya, Takehiko; Kashimoto, Kazuhisa Ibaraki, 302-0104, Japan CORPORATE SOURCE: SOURCE:

Regulatory Peptides (2004), 123(1-3), 193-199 CODEN: REPPDY; ISSN: 0167-0115

Elsevier B.V. Journal DOCUMENT TYPE: PUBLISHER:

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) act as neurotransmitters in numerous biol. responses. English LANGUAGE: Ā

extract (CSE), a causative factor of chronic obstructive pulmonary disease (CODD), in rat alveolar L2 cells. RT-PCR displayed the dominant expression of maRNA for the VIP-specific vpAc2 receptor in L2 cells, and VIP and the related peptides showed the specific binding activity and potent stimulation of adenylate cyclase. CSE at a concentration of 0.1% or higher induced significant apoptoric death of L2 cells. Interestingly, the addition of neuropeptides at a concentration of 10-11 M or higher in L2 cells with CSE (0.23%) resulted in significant attenuation of cell death with the deactivation of CSE-evoked caspase-3 activity. IK 312532 was much stable against the enzymic dispession compared to VIP, and the protective effect of IK 312532 was 1.6-fold higher than that of VIP. Taken together with our previous report showing that IK 312532 has long-acting relaxant activity in the lung, IK 312522 may be a potential candidate for drug treatment of asthma and COPD. (IK 312532; [Arg15, 20, 21, Leu17]-VIP) resulted in a significant improvement in metabolic stability and biol. activity. In the present study, we have stability and biol. activity. In the present study, we have signed the effect of VIP and its related peptides including long-acting VIP derivative (IK 312532) and PACAP27 on the cytotoxicity of cigarette smoke previously reported that the replacement of Lys by Arg, and Met by Leu in VIP

Section cross-reference(s): 4 2-6 (Mammalian Hormones) ខ

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 30 REFERENCE COUNT:

JUS COPYRIGHT 2007 ACS ON STN DUPLICATE 9 2003:449565 CAPLUS Full-text CAPLUS L33 ANSWER 9 OF 32 ACCESSION NUMBER:

139:209524 DOCUMENT NUMBER: TITLE:

Kosuke; Yajima, Takehiko; Kashimoto, Kazuhisa Misfolding of therapeutic peptides and the cytotoxicity of peptide fibrils Onoue, Satomi; Ohshima, Kelichi; Endo, AUTHOR (S):

Health Science Division, Itoham Food Inc., Moriya, Ibaraki, 302-0104, Japan CORPORATE SOURCE:

Peptide Science (2003), Volume Date 2002, 39th, SOURCE:

CODEN: PSCIFQ; ISSN: 1344-7661 Japanese Peptide Society English Journal DOCUMENT TYPE: PUBLISHER: LANGUAGE: Misfolding of peptides/proteins including  $\beta$ -amyloid, prion protein, and amylin generates the amyloidogenic isoforms with the abundant of eta-sheet structure, and these fibrils are causative agents for some neurodegenerative disorders. In addition to these toxic agents, some therapeutic peptides also displayed manner. Here, we demonstrated that incubation of human glucagon and salmon the conformational changes into  $\beta$ -sheet rich fibrils in a time-dependent AB

significant increase of fibril generation, and these fibrils are toxic neuron-like PC12 cells and fibroblast NIH-3T3 cells via activation of a calcitonin at the concentration of 5.0 mg/mL or higher resulted in a

apoptotic enzyme caspase-3. 6-3 (General Biochemistry) ပ္ပ

FOR THIS RE FORMAT THERE ARE 9 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE Section cross-reference(s): 1 REFERENCE COUNT:

OLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 10 2003:449537 CAPLUS Full-text 139:240629 CAPLUS L33 ANSWER 10 OF 32 ACCESSION NUMBER: DOCUMENT NUMBER:

Development of a new vasoactive intestinal peptide analogue and its topical administration system, dry powder inhalation

Health Science Division, Itoham Foods Inc., Moriya, Yuki; Yamada, Shizuo; Kimura, Ryohei; Kashimoto, Peptide Science (2003), Volume Date 2002, 39th, Amikawa, Satoko; Matsumoto, Asami; Ohmori, CODEN: PSCIFQ; ISSN: 1344-7661 Endo, Kosuke; Onoue, Satomi; Ibaraki, 302-0104, Japan 301-304 CORPORATE SOURCE: AUTHOR (S): PUBLISHER: SOURCE:

Japanese Peptide Society Journal English DOCUMENT TYPE: LANGUAGE:

well-established that VIP is effective in several types of bronchoconstriction in vivo and iv vitro, there are serious problems including the stability of VIP against enzymic digestion, its dosage form, and the undesired side effect due to the wide-distribution of VIP preferring receptors. Here, we have synthesized the stabilized VIP analog, and topical administration method has been developed for the respiratory systems such as trachea, bronchus and lung. novel drugs to treat asthma, since it was confirmed that VIP neuron was involved in the regulation of bronchodilation in human lung. Although it is Vasoactive intestinal peptide (VIP) has been considered as a candidate of 2-6 (Mammalian Hormones) AB

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT CC 2-6 (Mammal) REFERENCE COUNT:

LUS COPYRIGHT 2007 ACS on STN DUPLICATE 12 2002:636020 CAPLUS Full-text 138:19718 CAPLUS L33 ANSWER 11 OF 32 ACCESSION NUMBER: DOCUMENT NUMBER:

The neuropeptide PACAP attenuates  $\beta$ -amyloid

Ohshima, Keiichi; Yajima, Takehiko; Kashimoto, (1-42)-induced toxicity in PC12 cells Onoue, Satomi; Endo, Kosuke;

AUTHOR (S):

Health Science Division, Central Research Institute Itoham Foods Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki, CORPORATE SOURCE:

302-0104, Japan Peptides (New York, NY, United States) (2002), 23(8), 1471-1478

SOURCE:

CODEN: PPTDD5; ISSN: 0196-9781 Elsevier Science Inc. DOCUMENT TYPE: PUBLISHER:

English

of PC12 cells to AB. PACAP was at least 104-fold more effective than other neuropeptides including vasoactive intestinal peptide (VIP) and humanin, which correlated with the level of CAMP accumulation. Thus, our results suggested Pituitary adenylate cyclase activating polypeptide (PACAP) modulates neurotransmission in the central and peripheral nervous systems. In vitro and in vivo studies have shown the protective effects of PACAP against neuronal damage induced by ischemia and agonists of NMDA-type glutamate receptors. induced by  $\beta$ -amyloid. (A $\beta$ ) peptide, aggregation of which is a causative factor for Alzheimer's disease. PACAP (10-9 M) rescued 80% of decreased cell that PACAP attenuates  $A\beta$ -induced cell death in PC12 cells through an increase in cAMP and that caspase-3 deactivation by PACAP is involved in the signaling viability and 50% of elevated caspase-3 activity that resulted from exposure Here, we demonstrated that PACAP also protected against neuronal toxicity pathway for this neuroprotection. LANGUAGE: AB Pitui

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CC 2-5 (Mammal REFERENCE COUNT:

39

Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive Symposium, 27th, Sorrento, Italy, Aug. 31-Sept. 6, 2002 (2002), 472-473. Editor(8): Benedetti, Ettore; Itoham Foods Inc., Moriya, Ibaraki, 302-0104, Japan Pituitary adenylate cyclase-activating polypeptide Peptides 2002, Proceedings of the European Peptide inhibited the  $\beta$ -amyloid-induced neurotoxicity and Pedone, Carlo. Edizioni Ziino: Castellammare di Ohshima, Keiichi, Yajima, Takehiko, Kashimoto, COPYRIGHT 2007 ACS on STN DUPLICATE 13 CODEN: 69EYXG; ISBN: 88-900948-1-8 Conference 2004:28522 CAPLUS Full-text Endo, Kosuke; Onoue, Satomi; activation of caspase-3 Stabia, Italy. Kazuhisa English. CAPLUS L33 ANSWER 12 OF 32 ACCESSION NUMBER: CORPORATE SOURCE: DOCUMENT NUMBER: DOCUMENT TYPE: AUTHOR (S): LANGUAGE: SOURCE: AB

 $\mathsf{A}\beta extstyle{-}$  induced cell death is mediated via the cAMP-dependent signaling pathway and intestinal peptide (VIP) are closely related neuropeptides in terms of sequence, solution structure and physiol. functions. The effect of PACAP/VIP cells) in vitro was evaluated. PACAP27 (10-15-10-9 M) and VIP (10-9-10-7 M) on  $\beta$ -amyloid (A $\beta$ )-induced neurotoxicity in rat pheochromocytoma cells (PC12 showed significant neuroprotective effects against the  $A\beta$ -induced neuronal damage. The results indicated that PACAP27-induced neuroprotection against also caspase-3 deactivation. 2-5 (Mammalian Hormones) CC 2-5 (Mammal REFERENCE COUNT:

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT COPYRIGHT 2007 ACS on STN DUPLICATE 14 CAPLUS L33 ANSWER 13 OF 32

Pituitary adenylate cyclase activating polypeptide regulates the basal production of nitric oxide in PC12 2002:381009 CAPLUS Full-text 137:104139 ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

Onoue, Satomi; Endo, Kosuke; CORPORATE SOURCE: AUTHOR (S):

Yajima, Takehiko, Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., 1-2, Kubogaoka, Moriya, Ibaraki, 302-0104, Japan Life Sciences (2002), 71(2), 205-214 CODRN: LIFSAK, ISSN: 0024-3205 Elsevier Science Inc. Journal DOCUMENT TYPE: PUBLISHER: SOURCE:

cells. PAČAP decreased NO production in a dose-dependent manner, and the activators of protein kinase A and C also inhibited the NO production in PC12 RT-PCR expts. demonstrated that PC12 cells constitutively express the We investigated the neuronal role of VIP and PACAP in NO production in PC12 English cells. LANGUAGE:

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT mRNAs for neuronal NOS and the PACAP-specific (PACI) receptor, and we concluded that PACAP plays an important role in the regulation of nNOS activity through PAC1 receptor in PC12 cells. CC 2-10 (Mammalian Hormones)
REFERENCE COUNT: 40

ANSWER 14 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 15

Differences in biological activity between PACAP27 and CAPLUS Full-text 2003:48492 ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

VIP in PC12 cells depend on their N-terminal

Onoue, Satomi; Nagano, Yumiko; Endo,

AUTHOR (S):

Kosuke; Yajima, Takehiko; Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., Ibaraki, CORPORATE SOURCE:

302-0104, Japan

Pharmacology Reviews and Communications (2002), 12(4), 205-213

CODEN: PHRCF6; ISSN: 1028-8945 Taylor & Francis Ltd.

PUBLISHER:

SOURCE:

English Journal DOCUMENT TYPE: LANGUAGE:

activities of adenylate cyclase and nitric oxide synthase in neuron-like PC12 cells. N-terminal substitution between PACAP27 and VIP significantly affected the biol. activity, whereas it showed no significant effect on the C-terminal The functions of PACAP and VIP are thought to be exerted through the activation of three types of PACAP/VIP receptors: PACL, VPACL and VPAC2 raceptors. In neuronal tissues, these neuropeptides bind specifically to the PACAP-specific (PAC1) receptor and stimulate cAMP accumulation, and PACAP is approx. 103-fold more potent than VIP in these activities mediated through PAC1 receptor. In this study, the authors prepared a series of chimeric peptides in which the N-terminal residues of PACAP27/VIP replaced each other. α-helical structure of PACAP27/VIP. These results suggested that the random N-terminal structures in PACAP27/VIP play important roles in their activities The authors investigated the effects of these chimeric peptides on the and receptor specificity. 2-2 (Mammalian Hormones)

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMATA THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS CC 2-2 (Mammali REFERENCE COUNT:

CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 16 2002:495925 CAPLUS Full-text L33 ANSWER 15 OF 32 ACCESSION NUMBER:

137:261273 DOCUMENT NUMBER:

PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126 Onoue, Satomi; Ohshima, Kelichi; Endo, AUTHOR (S):

Koguke; Yajima, Takehiko; Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., Moriya, CORPORATE SOURCE:

Ibaraki, 302-0104, Japan SOURCE:

FEBS Letters (2002), 522(1-3), 65-70 CODEN: FEBLAL, ISSN: 0014-5793 Elsevier Science B.V. PUBLISHER:

Misfolding of the prion protein yields amyloidogenic isoforms, and it shows English Journa] DOCUMENT TYPE: LANGUAGE: A B

neuron-like PC12 cells. In particular, PACAP27 inhibited the neurotoxicity of PrF(106-126) at low concus. (>10-15 M), characterized by the deactivation of PrP(106-126)-stimulated caspase-3. The neuroprotective effect of PACAP27 was antagonized by the selective PKA inhibitor, H89, or the MAP kinase inhibitor, U0126. These results suggest that PACAP27 attenuates PrP(106-126)-induced exacerbating neuronal damage in neurodegenerative disorders including prion diseases. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) potently stimulate neuritogenesis and survival of neuronal cells in the central nervous system. Here, we tested these neuropeptides on neurotoxicity in PC12 cells induced by the prion protein fragment 106-126 [PPP (106-126)]. Concomitant application of neuropeptide with PrP(106-126)] inhibited the delayed death of

delayed neurotoxicity in PC12 cells by activating both PKA and MAP kinases mediated by PAC1, receptor. 14-10 (Mammalian Pathological Biochemistry)

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT CC 14-10 (Mamma REFERENCE COUNT:

COPYRIGHT 2007 ACS on STN DUPLICATE 17 2002:561620 CAPLUS Full-text 137:346531 CAPLUS L33 ANSWER 16 OF 32 ACCESSION NUMBER: DOCUMENT NUMBER: Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide attenuate

glutamate-induced nNOS activation and cytotoxicity Onoue, Satomi; Endo, Kosuke;

AUTHOR (S):

Vajima, Takehiko, Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., Ibaraki, CORPORATE SOURCE:

Regulatory Peptides (2002), 107(1-3), 43-47 CODEN: REPEDY, ISSN: 0167-0115 Moriya, 302-0104, Japan

Elsevier Science Ltd.

PUBLISHER:

SOURCE:

Journal English DOCUMENT TYPE:

activating polypeptide (PACAP) act as neurotransmitters in the central and peripheral nervous systems. Attention has been focused on these neuropeptides because among their numerous biol. activities, they have been confirmed to show neuroprotective effects against isohemia and glutamate-induced cytotoxicity. It is well established that glutamate has excitatory effects on neuronal cells, and that excessive glutamate shows potent neurotoxicity, especially in neuronal nitric oxide synthase-containing neurons. Glutamate stimulates the production of nitric oxide (NO) in neurons, and the NO We examined the effects of these neuropeptides on the glutamate-induced neural actions using PC12 cells, and we confirmed the important activities of PACAP/VIP on the production of NO as well as the delayed cell death stimulated by Both vasoactive intestinal peptide (VIP) and pituitary adenylate cyclasegenerated is tightly associated with the delayed death of neurons. LANGUAGE: AB

CC 2-5 (Mammalian Hormones)
REFERENCE COUNT: 37

glutamate.

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 18 1986;531504 CAPLUS Full-text L33 ANSWER 17 OF 32 ACCESSION NUMBER:

Changes of glycogen and ubiquinone contents in the rat 105:131504 DOCUMENT NUMBER: TITLE:

liver during hypovolemia and hepatic arterial ligation Asaki, Shinichiro; Tanaka, Souichi; Sugishita, Takeo; Endo, Kenzaburo; Yoshida, Satoru; Matsumoto, Akihiko AUTHOR (S):

Dep. Surg., Yokohama Kouwan Hosp., Yokohama, 231,

CORPORATE SOURCE:

Yokohama Igaku (1986), 37(2), 115-22 CODEN: YKIGAK; ISSN: 0372-7726 SOURCE:

Journal

DOCUMENT TYPE:

Changes in glycogen and ubiquinone contents in rat liver were examined after Japanese LANGUAGE: AB

contents of coenzyme Q10 and coenzyme Q9 at 4 h after blood removal and 3 h after hepatic artery occlusion were 76 and 103% of the control level, resp. Glycogenolysis was increased after blood removal and hepatic artery occlusion. 14-5 (Mammalian Pathological Blochemistry) removal of 10 mL/kg of blood and occlusion of the hepatic artery. The mean

ပ္ပ

Takayama, Yoshiko; Nakamura, Yoshikuni; Inoue, Yutaka; Corneal neuritogenesis promoter containing PACAP and Senju Pharmaceutical Co., Ltd., Japan; Itoham Foods Yabuta, Chiho; Azuma, Mitsuyoshi; Onoue, 2005:1171442 CAPLUS Full-text CAPLUS COPYRIGHT 2007 ACS on STN PCT Int. Appl., 65 pp. CODEN: PIXXD2 its derivative 143:446712 Japanese Satomi Patent FAMILY ACC. NUM. COUNT: PATENT INFORMATION: L33 ANSWER 18 OF 32 PATENT ASSIGNEE(S): ACCESSION NUMBER: DOCUMENT NUMBER: DOCUMENT TYPE: INVENTOR (S): LANGUAGE: SOURCE: TITLE:

NA, SL, ZA, Ä, £, g, PK A 20040423 20050421 20050421 GW, ð MZ, SK, YU, ZW, DE, PL, £ 25 £ 8 S, S, GY, CY, BY, KM, SE, VC, CA 2005-2563882 JP 2004-128581 JP 2004-330464 WO 2005-JP7609 8 E E E BW, KĠ, SD, UZ, SZ, BG, CT, BR, SC, US, SL, BE, IT, CI, RO, SD, AT, IS, CG, ďA, GE, TA ÄÄ, TZ, 20051103 MZ, TJ, HU, 20051103 AZ, DK, 7 F. AU, DE, RU, GR, Ü, 3 H. K. AT, 7 8 E GB, GB, AM, ĭ, ĕ, Ĕ, KZ, KZ, SK, B, ₩ GM, KG, FI, SI, SN, ¥ 8, 8 LR, NZ, TJ, PRIORITY APPLN. INFO.: NO, SY, ZW GH, BY, ES, WO 2005102375 AE, GE, NI, NI, SM, SM, AZ, CA 2563882 RW:

corneal perception accompanying therewith. For example, a peptide PACAP-27 was prepared, and examined for its effect on neuritogenesis in rabbits. Also, an eye drop containing PACAP-27 10 % was formulated. accompanying such reduction in corneal perception. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal perception and eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This corneal neuritogenesis promoter is useful as a drug for amelioration in corneal perception following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract pituitary adenylate cyclase-activating polypeptide), a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, a corneal neuritogenesis promoter aiming at improving corneal perception, treating dry It is intended to provide a corneal neuritogenesis promoter containing PACAP corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in neurodegeneration and dry eye symptom and corneal epithelial injury surgery, reduction in corneal perception accompanying corneal MARPAT 143:446712 OTHER SOURCE (S) : ΑB

A61K038-00 A61P027-02 ICM ü

63-6 (Pharmaceuticals) ပ္ပ

Section cross-reference(s): 2 127317-03-7P 128606-20-2P, PACAP38 129069-75-6P, PACAP27 137061-48-4P, Pituitary adenylate cyclase-activating polypeptide LI

43

10368-92-9P 700368-94-1P 700369-00-2P 735327-72-7P 868367-93-5P 700368-81-6P 700368-83-8P 700368-85-0P 868367-72-0P 868367-73-1P 868367-91-3P 868367-97-9P 868368-02-9P 868368-03-0P 700368-92-9P 700368-96-3P 700368-98-5P 700369-00 868367-64-0P 868367-65-1P 868367-70-8P 868368-04-1P 868368-05-2P 700368-87-2P 700368-90-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(corneal neuritogenesis promoter containing PACAP and its derivative) 700568-83-89-700588-83-700368-83-700368-87-2P 700368-96-3P 735327-72-7P 868367-65-1P 868367-70-8P 868367-91-3P Ħ

868367-97-9P 868368-02-9P 868368-03-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP 868368-04-1P 868368-05-2P

DATE

APPLICATION NO.

PATENT NO.

(corneal neuritogenesis promoter containing PACAP and its derivative) (Preparation); USES (Uses) CAPLUS 700368-83-8

alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-Lphenylalanyl-L-threonyl-L-d-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-Glycinamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-valyl-Lisoleucyl-L-leucyl- (9CI) (CA INDEX NAME) C Z

Absolute stereochemistry.

20041115

0880

PAGE 1-C

PAGE 1-D

PAGE 1-E

Bu-i

RN 700368-85-0 CAPLUS
CN L-Lysinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phistidyl-L-seryl-L-aspartyl-L-sparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-alanyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-arginyl-L-tyrosyl-L-laucyl-L-arginyl-L-tyrosyl-L

10/536880

Absolute stereochemistry.

PAGE 1-A

-NH2

Z Z

 $phenylalanyl-L-threonyl-L-\alpha-aspartyl-L-asparaginyl-L-tyrosyl-L-tyrosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-isole$ 700168-87-2 CAPLUS L-Argininamide, L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-

Absolute stereochemistry.

PACE 1-A

10/536880

PAGE 1-C

PAGE 1-E

700368-90-7 CAPLUS C R

phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-threonyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-alanyl-L-salanyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucyl-L-lysyl- (CA INDEX NAME) L-Argininamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-L-

Absolute stereochemistry.

PAGE 1-A

10/536880

PAGE 1-C

PAGE 1-E

700368-96-3 CAPLUS

 $L-Argininamide, \ L-histidyl-L-seryl-L-\alphaspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-glutaminyl-L-leucyl-L-arginyl-L-glutaminyl-L-leucyl-L-arginyl-L-leucyl-L-arginyl-L-leucyl-L-arginyl-L-leucyl-L-arginyl-L-leucyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-leucyl-L-arginy$ C RN

valy1-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 1-C

10/536880

PAGE 1-E

735327-72-7 CAPLUS

L-Argininamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-alanyl-L-asparaginyl-L-tyrosyl-L-threonyl-Larginyl-L-leucyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-Lvalyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-LL-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) C R

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-D

10/536880

868367-65-1 CAPLUS

phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-Lthreonyl-L-arginyl-L-leucyl-L-arginyl-L-glucaminyl-L-leucyl-Lalanyl-L-varyly-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-Lisoleucyl-L-leucylgycyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-Lisoleucyl-L-leucylglycyl-L-arginyl- (9C1) (CA INDEX NAME) L-Argininamide, L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-Z Z

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*
868367-70-8 CAPLUS 868367-70-8 CN N

valyl-L-phenylalanyl-L-threonyl-L-d-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-tyrosyl-L-threonyl-L-arginyl-L-arg L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-

STRUCTURE DIAGRAM IS NOT AVAILABLE 868367-91-3 CAPLUS

RN \*

L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 868367-97-9 CAPLUS

arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) L-Argininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-L-leucylglycyl-L-arginyl- (9CI) \* Z Z Z

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 868368-02-9 CAPLUS \* \*

L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-C Z

valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-tyrosyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-alanyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-aryyl-L-arginyl- (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

868368-03-0 CAPLUS

L-Argininamide, L-histidyl-L-seryl-L-lpha-aspartyl-L-alanyl-L-isoleucyl-\* N N

arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-Lleucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-(CA INDEX NAME) arginyl-L-valyl-L-arginyl-L-asparaginyl- (9CI)

### STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* . Z Z

868368-04-1 CAPLUS

arginyi. L. tyrosyl. L. arginyl. L. arginyi. L. glutaminyl. L. leucyl. L. alanyl. L. valanyl. L. valyl. L. arginyl. L. tyrosyl. L. leucyl. L. arginyl. L. arginyl. L. isoleucyl. L. leucyllylycyl. L. arginyl. L. arginyl. L. arginyl. L. arginyl. L. arginyl. L. glutaminyl. L. arginyl. L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-seryl+L-tyrosyl-L-seryl-L-(CA INDEX NAME) arginyl-L-valyl-L-arginyl-L-asparaginyl- (9CI)

### STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

868368-05-2 CAPLUS Z Z

 $\label{eq:local_local_local} L-threonyl-L-\alpha-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-arg$ L-Argininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-(CA INDEX NAME) leucylglycyl-L-arginyl- (9CI)

### STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* REFERENCE COUNT:

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2007 ACS on STN L33 ANSWER 19 OF 32 ACCESSION NUMBER:

Remedies for chronic lung disease containing VIP 2004:957355 CAPLUS Full-text 141:428007 DOCUMENT NUMBER: TITLE:

ör

Ogami, Masayoshi; Endo, Kosuke; Kashimoto, PACAP-derived peptides INVENTOR (S):

Jpn. Kokai Tokkyo Koho, 60 pp. Ito Ham Foods, Inc. Kazuhisa PATENT ASSIGNEE(S): SOURCE:

Japan

CODEN: JKXXAF Patent DOCUMENT TYPE:

Japanese LANGUAGE

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

20030416 JP 2003-112096 ' APPLICATION NO 20041111 DATE KIND 4 JP 2004315436 PATENT NO.

PRIORITY APPLN. INFO.:

JP 2003-112096 20030416

AB The invention relates to a remedy for chronic lung disease, eg.. chronic obstructive pulmonary disease and pulmonary emphysema, characterized by containing vasoactive intestinal peptide (VIP) or pituitary adenylate cyclase cells

ICS ü

A61P011-00; C07K014-47; C07K019-00; C12N015-09

63-6 (Pharmaceuticals) ដ

60703-95-9P Section cross-reference(s): 1 40077-57-4P, Vasoactive intestinal octacosapeptide (swine) 55

10/536880

791908-19-5P 791908-24-2P RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) 791908-18-4P 791908-23-1P 791908-28-6P 475083-13-7P 700369-00-2P 791837-97-3P 6785-24-3P 176785-25-4P 475083-13-7700368-81-6P 700368-89-8P 700368-85-0P 791908-17-3P 791908-27-5P 791908-22-0P 735327-71-6P 735327-72-7P 791908-16-2P 791908-21-9P 791908-26-4P 127317-03-7P 176785-24-3P 700368-79-2P 700368-81-6F 700368-87-2P 700368-90-7P 700369-02-4P 791837-98-4P 791908-20-8P 791908-25-3P

(remedies for chronic lung disease containing VIP or PACAP-derived peptides)

700368-87-2P 700368-90-7P 735327-72-7P 700368-83-8P 700368-85-0P 176785-24-3P

II

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(remedies for chronic lung disease containing VIP or PACAP-derived peptides)

176785-24-3 CAPLUS

 $phenylalanyl-L-threonyl-L-\alpha-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L$ L-Leucinamide, L-histidyl-L-seryl-L-lpha-aspartylglycyl-L-isoleucyl-L-(CA INDEX NAME) C Z

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-E

Bu-i

/NH2

C R

700168-81-8 CAPLUS Glycinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-E

\_ Bu-i

 $\label{eq:conversion} phenylalnyl-L-threonyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-leucyl-L-alanyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl-L-glycyl- (9CI) (CA INDEX NAME)$ 700168-85-0 CAPLUS L-Lysinamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-L-Z Z

Absolute stereochemistry.

### PAGE 1-A

PAGE 1-E

700368-87-2 CAPLUS Z Z

L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-targinyl-L-argi

Absolute stereochemistry.

10/536880

PAGE 1-C

700368-90-7 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-a-spartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-tryrosyl-L-threonyl-L-asparaginyl-L-glutaminyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-taugnyl-L-tyrosyl-L-taugnyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-taugnyl-L-tyrosyl-L-alanyl-L-alanyl-L-alanyl-L-tyrosyl-L-alanyl-L-tyrosyl-L-alanyl-L-typyl-L-C RN

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-D

PAGE 1-E

735327-72-7 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-a-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-alanyl-L-asparaginyl-L-tyrosyl-L-threonyl-Larginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-Lu-lyt-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucylL-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME) CN C

Absolute stereochemistry.

PAGE 1-C

PAGE 1-D

10/536880

PAGE 1-E

CAPLUS COPYRIGHT 2007 ACS on STN 2003:449513 CAPLUS Full-text L33 ANSWER 20 OF 32 ACCESSION NUMBER:

139:240497 DOCUMENT NUMBER:

AUTHOR (S):

TITLE:

The structural biology of VIP (2): biological activity of VIP is dependent on its secondary structure onoue, Satomi, Matamoto, Asami, Masamoto, Yumiko, Ohshima, Kelichi; Ohmori, Yuki; Yamada, Shizuo; Kimura, Ryohei; Yajima, Takehiko;

Kashimoto, Kazuhisa Health Science Division, Itoham Food Inc., Moriya,

Peptide Science (2003), Volume Date 2002, 39th, Ibaraki, 302-0104, Japan CORPORATE SOURCE:

225-228

SOURCE:

CODEN: PSCIFQ; ISSN: 1344-7661 Japanese Peptide Society Journal PUBLISHER:

long  $\alpha$ -helical structure plays a role in its biol. functions. Here, in order to address this issue, we chemical synthesized VIP analogs modified at the  $\alpha-$  helical region and evaluated their structural and biol. activities. The the presence of a randomized structure in the N-terminus and along  $\alpha\text{-helical}$  structure in the C-terminus. It is still unclear how the formation of the The conformational properties of vasoactive intestinal peptide (VIP) include results have shown that the  $\alpha$ -helical structure forming in 14 amino acid residues between positions 10 and 23 may be required for the biol. functions English DOCUMENT TYPE: LANGUAGE: AB The confor

2-2 (Mammalian Hormones) CC 2-2 (Mammali REFERENCE COUNT: of VIP.

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Powdery compositions and process for producing the L33 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION WIMBER: 2002:428689 CAPLUS FULL-text DOCUMENT NUMBER: 136:406898

TITLE: Powdery compositions and process

same

Onoue, Satomi; Endo, Kousuke; Kashimoto, Kazuhisa Itoham Foods Inc., Japan PCT Int. Appl., 63 pp. CODEN: PIXXD2 PATENT ASSIGNEE (S): INVENTOR (S):

DOCUMENT TYPE: LANGUAGE:

Japanese 1 FAMILY ACC. NUM. COUNT:

# PATENT INFORMATION: .

DATE	:	20011129		U, MC, NL,		20010326	20011129	20011129	20011129	20011129	E, MC, PT,		20030529	20030626	20001129	20010326	20011129	20011129
	:			II, L							NL, S				Æ	K	Ø	3
APPLICATION NO.	, , , , , , , , , , , , , , , , , , , ,	WO 2001-JP10445		DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,		JP 2001-88337	CA 2001-2430318	AU 2002-18503	JP 2001-364325	EP 2001-998330	DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		US 2003-432352	IN 2003-CN1013	JP 2000-362704	JP 2001-88337	JP 2001-364325	WO 2001-JP10445
DATE		20020606	ns.	DK, ES, F		20021003	20020606	20020611	20030207	20031001	, ES, FR, C		20040610	20050422				
KIND	:	A1	IN, KR, US	ζ,		Ø	A1	ď	4	A1	DE,	TR	Α1	Æ				
			Ğ,	GH,	TR.						GH,	ζ,		÷				
PATENT NO.		WO 2002043703	W: AU, CA,	RW: AT, BE, CH,	PT, SE,	JP 2002284703	2430318	200218503	2003034652	1348428	R: AT, BE,	IE, FI,	US 2004109827	IN 2003CN01013	PRIORITY APPLN. INFO.:			
PAT	;	WO				чZ	5	AU :	d'D	EP			SD	NI	PRIORITY			

can be easily handled in manufacturing and sustain a constant drug content due to the improved dispersibility. A powder composition containing glucagon, erythritol, and lactose was prepared, and evaluated as a dry powder inhalant. powdery drug and a filler and having an average particle size of  $\le 20~\mu m$  with Disclosed are powdery compns. obtained by mixing fine particles containing a a carrier having an aerodynamically acceptable particle size. These prepns. A 20011129 W 20011129 AB

A61K009-127; A61K009-19; A61K009-72; A61K047-10; A61K038-00 ICM A61K009-14 ü

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 12 63-6 (Pharmaceuticals) REFERENCE COUNT:

Development of a new derivative of vasoactive COPYRIGHT 2007 ACS on STN 2004:28756 CAPLUS Full-text 141:76535 CAPLUS ANSWER 22 OF 32 ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

intestinal peptide and its novel administration

Yoshihiro; Yamanaka, Masaya; Kondo, Masaaki; Hamanaka, Amikawa, Satoko; Matsumoto, Asami; Waki, system, dry powder inhalation Endo, Kosuke; Onoue, Satomi AUTHOR (S):

Symposium, 27th, Sorrento, Italy, Aug. 31-Sept. 6, 2002 (2002), 944-945. Editor(s): Benedetti, Ettore; Ibaraki, 302-0104, Japan Peptides 2002, Proceedings of the European Peptide Kazuya; Suitani, Yoshihiko; Kashimoto, Kazuhisa Health Science Div., Itoham Food Inc., Moriya, CORPORATE SOURCE:

SOURCE:

Pedone, Carlo. Edizioni Ziino: Castellammare di Stabia, Italy. CODEN: 69EYXG; ISBN: 88-900948-1-8 Conference

English DOCUMENT TYPE: LANGUAGE:

The synthesis of a new vasoactive intestinal peptide (VIP) named IK312532, .which was modified to increase its stability against enzymic digestion is discussed. AB

dependent manner. IX312532 was approx. 103-fold more potent in inducing relaxation than theophilline after histamine (10-5 M)-induced contraction and The formulation of a topical administration system, dry powder inhalation (DPI) is reported. Results showed that both IK312532 and VIP showed potent relaxation of isolated tracheal smooth muscle in a dose-

10/536880

of these peptides, and also revealed that the elimination of IK312532 was much slower than that of VIP. These results suggest that the duration of IK312532 was due to its stability against peptidase-induced elimination. On the other hand, when IK312532 was applied to the optimized DPI formula, erythritole-excipient/erythritol- carrier, the RF value was estimated to be up to 19.7%. However, erythritol-excipient/Pharmatose-carrier blend had a better RF value of 29.2%, indicating that the optimized formula of DPI was dependent on each pharmaceutical agent. Considered with other peptides, this formula, with the use of erythritol for the excipient and/or carrier, is applicable to the trypsin, to a solution of IX312532 or VIP showed the time-dependent digestion including The addition of peptidase, had an EC50 value of  $2.0 \times 10^{-7} M.$ peptide/protein.

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT CC 63-6 (Pharmaceuticals)
REFERENCE COUNT:- 2

The relaxation effects of VIP and its C-terminal deleted peptides on mouse stomach COPYRIGHT 2007 ACS on STN Full-text 2002:517561 CAPLUS 137:363243 CAPLUS L33 ANSWER 23 OF 32 ACCESSION NUMBER: DOCUMENT NUMBER:

Nagano, Yumiko; Matsumoto, Asami; Onoue, Satomi; Harada, Sunao; Mizumoto, Takahiro; Suitani, Yoshihiko; Hamanaka, Kazuya;

AUTHOR(S):

Health Science Division, ITOHAM FOODS INC., Moriya, Ibaraki, 302-0104, Japan Peptide Science (2002), Volume Date 2001, 38th, CORPORATE SOURCE:

Kashimoto, Kazuhisa

CODEN: PSCIFQ; ISSN: 1344-7661 147-150

SOURCE:

Japanese Peptide Society English Journal DOCUMENT TYPE: PUBLISHER: LANGUAGE:

confirmed the most potent activity of VIP among tested peptides. We, therefore, have been interested in this relaxation activity and structure of VIP, so we clarified the relationship between its structures and activities of fragment of VIP, which was necessary for a potent relaxation effect on mouse peptides of this family on mouse stomach using some family peptides, and we investigations gave us further information concerning with a min. peptide Some brain-gut/gastrointestinal peptides, belonging to glucagon-secretin family, are well-known to have the potent inhibitory effects on gastric motility. In this study, we investigated the relaxation effects of some shortened VIP-derivs., which were truncated at N- or C- terminal ends. stomach. AB

2-2 (Mammalian Hormones) CC 2-2 (Mammal) REFERENCE COUNT:

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT Ξ

COPYRIGHT 2007 ACS on STN 1998:550347 CAPLUS Full-text CAPLUS L33 ANSWER 24 OF 32 ACCESSION NUMBER:

Insulating film, semiconductor device using such film, Matsubara, Takahisa, Noguchi, Nobu; Ito, Shinya; Ota, and method for manufacture thereof 129:224450 DOCUMENT NUMBER: INVENTOR (S):

Endo, Kazuhiko; Tatsumi, Toru; Matsumoto, Takashi; Nakamae, Masahiko; Horiuchi, Noriaki; Matsumoto, Akira; Ishigami,

NEC Corp., Japan Jpn. Kokai Tokkyo Koho, 19 Yoshishige PATENT ASSIGNEE(S):

ď

CODEN: JKXXAF Patent Japanese

LANGUAGE: FAMILY ACC. NUM. COUNT:

DOCUMENT TYPE:

	DATE	 19970605		19971202	19971202	20000526	19961202	19970605	
	APPLICATION NO.	JP 1997-148017		US 1997-982585	GB 1999-11186	US 2000-579474	JP 1996-321694 A	JP 1997-148017 A	
	DATE	 19980821	20011112	20000718	20000719	20020416			
	KIND	 æ	B2	Æ	æ	B1			
PATENT INFORMATION:	PATENT NO.	JP 10223625	JP 3228183	US 6091081	GB 2334818	US 6372628	PRIORITY APPLN. INFO.:		

GB 1997-25525 A3 19971202 US 1997-92525 A3 19971202 US 1997-982585 A3 19971202 An insulating film is obtained by coating H-containing diamond-like C onto 1 surface of amorphous C fluoride film and then coating a Si(O,N), Si3N4, or SiO2 films containing excess Si. Via holes are formed by anisotropic etching with O plasma of the diamond-like C film and amorphous C fluoride film. AB

H01L021-314 ICM ü

HOILO21-3065; HOILO21-768; HOILO21-205 76-3 (Electric Phenomena)

ပ္ပ

111:154419 Radical polymerization of vinyl esters with a bulky tert-butyl group
Otsu, Takayuki, Matsumoto, Akikazu,
Otsu, Takayuki, Matsumoto, Akikazu,
Dep. Appl. Chem., Osaka City Univ., Osaka, Japan
Memoirs of the Faculty of Engineering, Osaka City
University (1988), 29, 161-9
CODEN: MFEOAR, ISSN: 0078-6659 COPYRIGHT 2007 ACS on STN:554419 CAPLUS Full-text 1989:554419 CAPLUS English Journal CAPLUS ANSWER 25 OF 32 ACCESSION NUMBER: CORPORATE SOURCE: DOCUMENT NUMBER: TITLE: DOCUMENT TYPE: AUTHOR (S):

The radical polymerization reactivities of vinyl pivalate (I), vinyl benzoate (II), and vinyl p-tert-butylbenzoate (III) were investigated and compared with that of vinyl acetate (IV). The polymerization rates in bulk were in the following order: IV > I > III. The polymerization reactivities were lower than those of the aliphatic caroxylates, and the introduction of a bulky These tert-Bu group into II increased the polymerization activity. The overall activation energy of the polymerization of I in benzene was 109 kJ/mol. These polymers, except for IV, were thermally stable (Tmax = 330-350°). The tacticity of the polymers was determined by 13C NMR after their conversion to poly(viny) acetate) by hydrolysis and acetylation.

35-3 (Chemistry of Synthetic High Polymers) LANGUAGE: AB The r

ប្ជ

1999253196 MEDLINE Full-text PubMed ID: 10319638 Invasive thymoma associated with pure red cell aplasia and Ishiwa N; Yamamoto Y; Tanaka S; Yamada R; Wada N; Kumakiri Y; Takahashi M; Kasahara A; Endo K; Yoshida S; liver metastasis: a case report. MEDLINE on STN L33 ANSWER 26 OF 32 ACCESSION NUMBER: 1 DOCUMENT NUMBER:

AUTHOR:

10/536880

Department of Surgery, Yokohama City Kowan Hospital, Japan. Kyobu geka. The Japanese journal of thoracic surgery, (1999 May) Vol. 52, No. 5, pp. 426-9. May) Vol. 52, No. 5, pp. 426-9. Journal code: 0413533. ISSN: 0021-5252. Journal; Article; (JOURNAL ARTICLE) Entered STN: 18 Jun 1999 Last Updated on STN: 18 Jun 1999 Entered Medline: 4 Jun 1999 Matsumoto A; Yoshida S Priority Journals (CASE REPORTS) Japanese CORPORATE SOURCE: DOCUMENT TYPE: PUB. COUNTRY: FILE SEGMENT: ENTRY MONTH: ENTRY DATE: LANGUAGE: ABSTRACT SOURCE:

suspected by imaging procedures. Left lateral segmental resection of liver was performed and histo-pathological examination proved the tumor to be liver metastasis of thymoma. He was received 80 Gy irradiation after incomplete resection of thymoma. In the course of time he contracted pure red cell aplasia. But he is well controlled medically and alive 7 years after the was A case of invasive thymoma associated with pure red cell aplasia and liver metastasis was reported. A 57-year-old male was admitted to our hospital because of hepatic abnormal shadow on computed tomography. Malignant tumor surgery

Check Tags: Male English Abstract CONTROLLED TERM:

Liver Neoplasms: RA, radiography \*Liver Neoplasms: SC, secondary

\*Red-Cell Aplasia, Pure: ET, etiology Thymoma: CO, complications \*Thymoma: PA, pathology Middle Aged

Thymoma: RA, radiography SC, secondary \*Thymoma:

Thymus Neoplasms: CO, complications \*Thymus Neoplasms: PA, pathology

Tomography, X-Ray Computed

L33 ANSWER 27 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation STN

6

Vasoactive intestinal peptide protects rat alveolar L2 cell from the cytocoxicity of cigarette smoke.

Onoue, Satomi [Reprint Author]; Endo.

Kosuke [Reprint Author]; Ohmori, Yuki; Yamada, Shizuo; 2003:433741 BIOSIS Full-text PREV200300433741 ACCESSION NUMBER: DOCUMENT NUMBER: AUTHOR (S): TITLE:

Health Sci. Div., Itoham Foods Inc., Ibaraki, 302-0104, Kimura, Ryohei; Yajima, Takehiko; Kashimoto, Kazuhisa [Reprint Author] CORPORATE SOURCE:

and Related Peptides. Hakone, Japan. September 01-04, 2003. ISSN: 0167-0115 (ISSN print). Regulatory Peptides, (15 August 2003) Vol. 115, No. 1, pp. Meeting Info.: 6th International Symposium on VIP, PACAP

Japan

SOURCE:

Conference, Abstract, (Meeting Abstract) Conference; (Meeting) DOCUMENT TYPE:

Entered STN: 17 Sep 2003 LANGUAGE: ENTRY DATE:

C	٥
œ	
×	
ď	
"	
٧	•
2	5
_	

CONCEPT CODE:	Last Updated on STN: 17 Sep 2003 General biology - Symposia, transactions and proceedings	000
	U00200 Blochemistry studies - Nucleic acids, purines and pyrimidines 10062 Blochemistry studies - Proteins, peptides and amino acids 10064 Enzymes - General and comparative studies: coenzymes 10802 Respiratory system - Physiology and biochemistry 16004 Respiratory system - Physiology 16006 Toxicology - General and methods 22501	LAN
INDEX TERMS:	epts corv System (Respiration)	
INDEX TERMS:	Diseases chronic obstructive pulmonary disease: respiratory system disease, CODA The Disease CODA	
INDEX TERMS:		
INDEX TERMS:		
	Lingsitzer Muridae 86375 Sunbr Taxa	IND
	Juyor, Jaka Rodentia, Mammalia, Vertebrata, Chordata, Animalia Organism Name L2 cell line (cell line): rat alveolar cells rat (comnon)	IND
REGISTRY NUMBER:	Taxa Notes Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates 9001-60-9 (LDH)	GNI
	9001-60-9 (lactate dehydrogenase) 189592-56-7 (caspase-3) 141907-41-7 (matrix metalloproteinase) 141907-41-7 (MMP) 37221-79-7 (vasoactive intestinal peptide)	GNI GNI
L33 ANSWER 28 OF 32 STN ACCESSION NUMBER:	2207:21901 BIOSIS Full-text	IND
DOCUMENT NUMBER: TITLE: AUTHOR(S):	PREVZ00700034563 Alpha-helical structure of vasoactive intestinal peptide is essential to its biological functions. Oncue. Satomi [Reprint Author]; Matsumoto, Asami; Ohmori, Yuki; Yamada, Shizuo; Liu, Baosheng;	ONI
CORPORATE SOURCE: SOURCE:	Yajima, Takehiko Ito Life Sci Inc. Ibaraki 3020104, Japan Ito Life Sci Inc. Ibaraki 3020104, Japan Riegel, M [Editor]; Prickin, M [Editor]; Gilon, C [Editor]; Slaninova, J [Editor] (2005) pp. 742-743. Peptides 2004, Proceedings:RIDGES DEFYEEN DISCIPLINES. Publisher: KENES INTERNATIONAL, 17 RUE DU CENDRIER; PO BOX 1726, GENEVA 1, CH-1211, SMITZERLAND.	ORG
	Meeting into:: ifd international Peptide Symposium/28th European Peptide Symposium. Prague, CZECH REPUBLIC. September 05 -10, 2004.	REG

nitric oxide synthase [EC 1.14.13.39]; adenylate cyclase [EC 4.6.1.1]; PACAP; neurite outgrowth factor; vasoactive intestinal peptide [VIP]: metabolic-drug diabetes: endocrine disease/pancreas, metabolic disease, dementia: nervous system disease, behavioral and mental disorders, drug therapy
Dementia (MeSH) impotence: reproductive system disease/male, behavioral
and mental disorders, drug therapy
Impotence (MeSH) Entered STN: 27 Dec 2006

Last Updated on STN: 27 Dec 2006

Behavioral biology - Human behavior

Biochemistry studies - Proteins, peptides and amino acids Pharmacology - General 22002 Pharmacology - Drug metabolism and metabolic stimulators 22003 Nervous system - Pathology 20506 Psychiatry - Psychopathology, psychodynamics and therapy 34508 Super Taxa Primates; Mammalia; Vertebrata; Chordata; Animalia asthma: respiratory system disease, immune system disease, drug therapy Asthma (MeSH) Enzymes - General and comparative studies: coenzymes inflammation: immune system disease, drug therapy Inflammation (MeSH) Animals, Chordates, Humans, Mammals, Primates, Pharmacology - Clinical pharmacology 22005 Immunology - Immunopathology, tissue immunology 13020 Pathology - Therapy 12512
Metabolism - Metabolic disorders 13020
Respiratory system - Pathology 16506
Esproductive system - Pathology 16506
Endocrine - Pancreas 17008 Vertebrates 125978-95-2 (nitric oxide synthase) drug therapy Diabetes Mellitus (MeSH) Chemicals & Biochemicals ISBN: 965-90833-0-0(H). Book; (Book Chapter) Conference; (Meeting) Classifier Hominidae 86215 35500 Major Concepts Pharmacology Organism Name Taxa Notes Diseases Diseases Diseases Diseases Diseases Allergy English 21002 REGISTRY NUMBER: CUMENT TYPE: NCEPT CODE: DEX TERMS: TRY DATE: NGUAGE: GANISM:

73

Taxa Notes Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rođents, Vertebrates

	10/53680	
	125978-95-2 (EC 1.14.13.39) 9012-42-4 (adenylate cyclase) 9012-42-4 (EC 4.6.1.1) 137061-48-4 (PACAP) 37221-79-7 (vasoactive intestinal peptide)	
L33 ANSWER 29 OF 3 STN ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:	32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on 2003:213128 BIOSIS Full-text PREV200300213128 Structure-activity relationship of vasoactive intestinal	
AUTHOR(S):		
CORPORATE SOURCE:	Kashimoto, Kazuhisa Dept. Biopharu., Sch. Pharm. Sci., Univ. Shizuoka, Shizuoka, 422-8526, Japan	
SOURCE:	Journal of Pharmacological Sciences, (2003) Vol. 91, No. Supplement I, pp. 237P. print. Meeting Info.: 76th Annual Meeting of the Japanese Pharmacological Society. Fukuoka, Japan. March 24-26, 2003.	
DOCUMENT TYPE:	ISSN: 1347-8613 (ISSN print). Conference; (Meeting)	
LANGUAGE: ENTRY DATE: CONCEPT CODE:	Conference, Abstract; (Meeting Abstract) English Entered STN: 30 Apr 2003 Last Updated on STN: 30 Apr 2003 General biology - Symposia, transactions and proceedings	
	50 tid	
INDEX TERMS:	Muscle - Physiology and blochemistry 17504 Major Concepts Biochamistry and Molamilar Biochunion	
INDEX TERMS:	. i.e	
INDEX TERMS:	System, retaration; Stomain: digestive system Chemicals & Biochemical; carbachol; hormone: asparagine; asparagine acid; carbachol; hormone: secretion; methionine; neuropeptide: amino acid sequences; threonine; vasoactive intestinal peptide [VIP]: analogues, structure-activity relationships;	
INDEX TERMS:	Vasoactive incestinal peptide receptor [VIP receptor] Miscellaneous Descriptors	
ORGANISM:	Vasoriation Classifier 86375 Muridae 86375 Super Taxa Rodentia, Mammalia, Vertebrata, Chordata, Animalia Organism Name (common)	
	Taxa Notes	

```
2003:413739 BIOSIS Full.text
PREV200300433731
Pharmacological usefulness of dry powder inhaler of a novel
vasoactive intestinal peptide (VIP) analogue as anti-asthma
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Meeting Info.: 6th International Symposium on VIP, PACAP and Related Peptides. Hakone, Japan. September 01-04, 2003. ISSN: 0167-0115 (ISSN print).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Parts, Structures, & Systems of Organisms eosinophil: blood and lymphatics, immune system; granulocyte: blood and lymphatics, immune system; lung: respiratory system; neutrophil: blood and lymphatics, immune system; respiratory system
                                                                                                                                                                                                                                                                                                                                                                                                           agent.
Ohmori, Y. [Reprint Author]; Yamada, S. [Reprint Author];
Kimura, R. [Reprint Author]; Onoue, S.;
Matsumoto, A.; Endo, K.; Iwanaga, T.;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Regulatory Peptides, (15 August 2003) Vol. 115, No. 1, pp.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Biochemistry studies - Proteins, peptides and amino acids
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Entered STN: 17 Sep 2003
Last Updated on STN: 17 Sep 2003
General biology - Symposia, transactions and proceedings
                                                                                                                                                                                                                                                  6
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sch. Pharm. Sci. and COE21, Univ. of Shizuoka, Shizuoka,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               16004
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             34508
                                                                                                                                                                                                                                             L33 ANSWER 30 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Pharmacology; Pulmonary Medicine (Human Medicine,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Blood - Blood and lymph studies 15002
Blood - Blood cell studies 15004
Respiratory system - Physiology and biochemistry
Respiratory system - Pathology 16006
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Pharmacology - Respiratory system 22030
Immunology - General and methods 34502
Immunology - Immunopathology, tissue immunology
56-84-8 (asparaginic acid)
51-83-2 (carbachol)
59-51-80 (methionine)
63-68-30 (methionine)
72-19-50 (threonine)
80-68-20 (threonine)
37221-79-7 (vasoactive intestinal peptide)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Conference, (Meeting)
Conference, Abstract, (Meeting Abstract)
English
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  12512
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Cytology - Animal 02506
Cytology - Human 02508
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 02508
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Pathology - Therapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Medical Sciences)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   35500
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Allergy 35500
Major Concepts
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               52. print
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          00520
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       10064
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Japan
                                                                                                                                                                                                                                                                                              ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              CORPORATE SOURCE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 DOCUMENT TYPE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  CONCEPT CODE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                LANGUAGE:
ENTRY DATE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 INDEX TERMS:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          INDEX TERMS:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          INDEX TERMS:
                                                                                                                                                                                                                                                                                                                                                                                                                                      AUTHOR (S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 SOURCE:
```

10/536880

3130-87-8Q (asparagine) 70-47-3Q (asparagine)

REGISTRY NUMBER:

IK312532: antiasthmatic-drug, inhalation administration, powder; vasoactive intestinal peptide [VIP]: author]; Yamanaka, M. [Reprint author]; Kondo, M. [Reprint author]; Hamanaka, K. [Reprint author]; Suitani, Y. author]; Hamanaka, K. [Reprint author]; Suitani, Y. [Reprint author]; Rashimoto, K. [Reprint author] Health Science Div., Itcham Food Inc., 1-2-1 Kubogaoka, Moriya, Ibbaraki, 302-0104, Japan Journal of Peptide Science, (2002) Vol. 8, No. Supplement, antiasthmatic-drug, analogue, inhalation administration pp. S214. print. Meeting Info.: 27th European Peptide Symposium. Sorrento, Italy. August 31-September 06, 2002. ISSN: 1075-2611. 6 Enfered STN: 30 Oct 2002 Last Updated on STN: 30 Oct 2002 General biology - Symposia, transactions and proceedings Development of a new derivative of vasoactive intestinal peptide and its novel administration system, dry powder Rodentia; Mammalia; Vertebrata; Chordata; Animalia Primates; Mammalia; Vertebrata; Chordata; Animalia Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation asthma: immune system disease, respiratory system [Reprint author]; Amikawa, S. [Reprint author];
Matsumoto, A. [Reprint author]; Waki, Y. [Reprint Animals, Chordates, Humans, Mammals, Primates, respiratory system disease Methods & Equipment drug powder inhaler: drug delivery device 37221-79-7 (vasoactive intestinal peptide) Conference; Abstract; (Meeting Abstract) inhalation. Endo, K. [Reprint author]; Onoue, S. guinea-pig (common): animal model 2002:557424 BIOSIS Full-text PREV200200557424 Conference; (Meeting Poster) human (common): patient Chemicals & Biochemicals Lung Diseases (MeSH) pulmonary disease: Conference, (Meeting) Hominidae 86215 Caviidae 86300 Asthma (MeSH) 37221-79-7 (VIP) Vertebrates Organism Name Organism Name Super Taxa disease Classifier Super Taxa Classifier Taxa Notes L33 ANSWER 31 OF ACCESSION NUMBER: DOCUMENT NUMBER: CORPORATE SOURCE: REGISTRY NUMBER: DOCUMENT TYPE: LANGUAGE: ENTRY DATE: INDEX TERMS: INDEX TERMS: INDEX TERMS: AUTHOR (S): ORGANISM: ORGANISM:

## 10/536880

Journal of Peptide Science, (2002) Vol. 8, No. Supplement, peptide derivative: bronchodilator-drug, nasal administration; vasoactive intestinal peptide receptor pp. S170. print. Meeting Info.: 27th Buropean Peptide Symposium. Sorrento, Italy. August 31-September 06, 2002. ISSN: 1075-2617. Biochemistry studies - General 10060 Biochemistry studies - Proteins, peptides and amino acids Biochemistry studies - Proteins, peptides and amino acids transactions and proceedings 6 Endo, K. [Reprint author]; Onoue, S. [Reprint author]; Ohshima, K.; Yajima, T.; Kashimoto, K. Chemicals & Biochemicals vasoactive intestinal vasoactive intestinal L33 ANSWER 32 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation Pituitary adenylate cyclase activating polypeptide inhibited the beta-amyloid-induced neurotoxicity and asthma: immune system disease, respiratory system [Reprint author] Itoham Foods Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki, Enzymes - General and comparative studies: coenzymes 20504 Immunology - Immunopathology, tissue immunology Allergy 35500 Nervous system - Physiology and biochemistry Nervous system - Pathology 20506 37221-79-7D (vasoactive intestinal peptide) (vasoactive intestinal peptide) 22030 Conference; (Meeting)
Conference; Abstract; (Meeting Abstract) 16006 Meeting Abstract; Meeting Poster Methods & Equipment Jet Haler: drug delivery device Miscellaneous Descriptors Pharmacology - General 22002 Pharmacology - Respiratory system Major Concepts
Pharmaceuticals (Pharmacology) Entered STN: 30 Oct 2002 Last Updated on STN: 30 Oct 2002 Pathology - Therapy 12512 Respiratory system - Pathology 2002:557266 BIOSIS Full-text Conference; (Meeting Poster) General biology - Symposia, Nervous system - Pathology 02506 activation of caspase-3. Cytology - Animal Asthma (MeSH) PREV200200557266 302-0104, Japan 37221-79-7 disease Diseases English 10064 ACCESSION NUMBER: DOCUMENT NUMBER: CORPORATE SOURCE: REGISTRY NUMBER: DOCUMENT TYPE: CONCEPT CODE: INDEX TERMS: INDEX TERMS: INDEX TERMS: INDEX TERMS: INDEX TERMS: INDEX TERMS: ENTRY DATE: AUTHOR (S): LANGUAGE: SOURCE: TITLE:

CONCEPT CODE:

Biochemistry and Molecular Biophysics; Nervous System Alzheimer's disease: behavioral and mental disorders, Parts, Structures, & Systems of Organisms neuron: nervous system nervous system disease (Neural Coordination) INDEX TERMS: INDEX TERMS

PAC1 receptor; beta-amyloid: neurotoxicity; caspase-3; humanin; pituitary adenylate cyclase activating Alzheimer Disease (MeSH) Chemicals & Biochemicals INDEX TERMS

signaling pathway; Meeting Abstract; Meeting Poster polypeptide; vasoactive intestinal peptide Miscellaneous Descriptors

> INDEX TERMS ORGANISM:

Rodentia; Mammalia; Vertebrata; Chordata; Animalia 86375 Classifier Muridae Super Taxa

Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates PC12 cell line Organism Name Taxa Notes

polypeptide) 37221-79-7 (vasoactive intestinal peptide)

169592-56-7 (caspase-3) 137061-48-4 (pituitary adenylate cyclase activating

REGISTRY NUMBER:

10/536880

FILE 'REGISTRY' ENTERED AT 12:24:03 ON 30 JAN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS) file registry

Property values tagged with IC are from the ZIC/VINITI data file provided by Infochem.

HIGHEST RN 918776-45-1 HIGHEST RN 918776-45-1 29 JAN 2007 29 JAN 2007 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30,

Please note that search-term pricing does apply when conducting SmartSELECT searches.

predicted properties as well as tags indicating availability of experimental property data in the original document. For information REGISTRY includes numerically searchable data for experimental and on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> file caplus

FILE 'CAPLUS' ENTERED AT 12:24:08 ON 30 JAN 2007
USE IS SUBJECT TO THE THEMS OF YOUR STR CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERNS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6 FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

PLU=ON AMI?/NTE PLU=ON HSDA[IV]FT[DEA][SND]Y[ST]R[YL => d stat que L9 L3 113096 SEA FILE=REGISTRY ABB=ON L6 54 SEA FILE=REGISTRY ABB=ON


L6 AND L3 ឌ FRQLAVRRYLAA/SQSP 30 SEA FILE=REGISTRY ABB=ON PLU=ON 4 SEA FILE=CAPLUS ABB=ON PLU=ON L8

.> d stat que L16

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation:

Uploading L10.str



ring nodes :

94 95

24-37 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62 23-76 23-24 21-46 22-38 22-101 20-21 20-75 18-74 19-45 16-17 chain bonds

35-36 35-100 36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-27-84 28-49 29-30 29-104 30-50 31-32 31-98 26-48 27-28

62-63 63-64 64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73 81-83 84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97

ring bonds 91-95 91-9

92-93 93-94 94-96 95-96

.-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28 i-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62 16-17 16-69

94-96 normalized bonds : 91-95 91-92 92-93 93-94 Match level

33-99 35-100

31-98

exact bonds :

33-34 60-61

78-79 79-80 80-81

70-71 71-72 71-73 77-78

91-104 94-97

88-90

65-68 66-68 67-68 69-70 81-83 85-86 86-87 87-88 88-89

36-101 63-64

38-39 38-54 39-40 39-41 55-56 56-57 57-58

24-37

23-76 32-51 29-61

23-24 31-32 58-61

22-101 29-104 30-50

22-38

20-75 21-46 28-49 29-30

20-21 27-84

19-45 27-28

18-74 26-48

18-19 25-37 25-77 35-36

10/536880

92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:CLASS 98:CLASS CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 67:CLASS 77:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 76 : CLASS 86:CLASS 56:CLASS 66:CLASS 36:CLASS 46:CLASS 65:CLASS 75 : CLASS 83:CLASS 84:CLASS 85:CLASS 35:CLASS 45:CLASS 55:CLASS 74 : CLASS 63:CLASS 64:CLASS 34:CLASS 44:CLASS 54: CLASS 73:CLASS 33:CLASS 43:CLASS 53:CLASS 101:CLASS 104:CLASS 22:CLASS 32:CLASS 42:CLASS 62:CLASS 72:CLASS 82:CLASS 52:CLASS CLASS 3:CLASS 11:CLASS 71:CLASS 39:CLASS 100:CLASS 48:CLASS 50:CLASS 60:CLASS 68:CLASS 70:CLASS 78:CLASS 28:CLASS 30:CLASS 38:CLASS 40:CLASS 58:CLASS 80:CLASS 88:CLASS 90:CLASS

11 SEA FILE=REGISTRY SSS FUL L10 9 SEA FILE=CAPLUS ABB=ON PLU=ON L15 L15 L16

=> s (L9 or L16) not L32 L34 6 (L9 OR L16) NOT L32

32-51

=> file toxcenter FILE 'TOXCENTER' ENTERED AT 12:24:42 ON 30 JAN 2007 COPYRIGHT (C) 2007 ACS

FILE COVERS 1907 TO 30 Jan 2007 (20070130/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MeSH terms.and See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2007 vocabulary.


=> d stat que I 16

54 SEA FILE=REGISTRY ABB=ON PLU=ON HSDA[IV]FT[DEA][SND]Y[ST]R[YL ] RRQLAVRRYLAA/SQSP

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT

Structure attributes must be viewed using STN Express query preparation:

Uploading L10.str



2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62 16-69 16-17 chain bonds 15-43

18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37

27-84 28-49 29-30 29-104 30-50 31-32 31-98 32-51 35-36 35-100 36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-26-48 27-28 25-77

64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73 88-90 91-104 94-97 85-86 86-87 87-88 88-89 62-63 63-64 84-85 81-83 60-61 81-82 78-79 59-61

94-96 95-96 93-94 92-93 exact/norm bonds : 91-92 ring bonds :

78-79 79-80 80-81 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 29-104 30-50 31-32 32-51 59-61 58-61 56-57 57-58 66-68 67-68 69-70 70-71 71-72 71-73 77-78 91-104 94-97 38-54 39-40 39-41 55-56 28-49 29-30 88-90 27-84 88-89 27-28 87-88 35-36 36-101 38-39 16-69 18-74 26-48 86-87 25-37 16-17 81-83 85-86 18-19 89-59 63-64 exact bonds 15-43 24-47

33-99 35-100 31-98

normalized bonds : 91-95 91-92 92-93 93-94 94-96

95-96

4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS SS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 26:CLASS 25:CLASS 23:CLASS 24:CLASS 3:CLASS 4:C S 12:CLASS 22:CLASS 11:CLASS 21:CLASS 19:CLASS level 20:CLASS 28:CLASS 10:CLASS

57: CLASS 36:CLASS 46:CLASS 56 : CLASS 35:CLASS 45:CLASS 55:CLASS 34:CLASS 44:CLASS 54 : CLASS 33:CLASS 43:CLASS 53:CLASS 42:CLASS 52:CLASS 32:CLASS 31:CLASS 41:CLASS 51:CLASS CLASS 39:CLASS CLASS 59:CLASS 30:CLASS 38:CLASS 40:CLASS 48:CLASS 50:CLASS

66:CLASS 76:CLASS 65:CLASS 75:CLASS 64:CLASS 74:CLASS 63:CLASS 73:CLASS 62:CLASS 72:CLASS 61:CLASS 69:CLASS 71:CLASS 60:CLASS 68:CLASS 58:CLASS

92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:CLASS 98:CLASS 85:CLASS 86:CLASS 83:CLASS 84:CLASS 82:CLASS 79:CLASS 81:CLASS 89:CLASS 91:Atom 70:CLASS 78:CLASS 80:CLASS 88:CLASS 90:CLASS

101:CLASS 104:CLASS 100:CLASS

L6 OR L15 SEA FILE=REGISTRY SSS FUL L10 SEA FILE=REGISTRY ABB=ON PLU=ON L SEA FILE=TOXCENTER ABB=ON PLU=ON 11 62

L15 L26 L28

0 L28 NOT L29 => s L28 not L29 L35 0 L2 => d ibib abs hitind hitstr L34 1-6
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L34 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER; 2004:651355 CAPLUS Full-text ACCESSION NUMBER; DOCUMENT NUMBER: TITLE:

8

PACAP and VIP peptide derivatives as antiinflammatory

Yamada, Shizuo, Ogami, Masayoshi; Kashimoto, Kazuhisa Ito Ham Foods, Inc., Japan Jpn. Kokai Tokkyo Koho, 62 pp. agents Yamada, INVENTOR(S): PATENT ASSIGNEE(S): DOCUMENT TYPE: SOURCE:

Patent

Japanese

LANGUAGE:

COUNT: FAMILY ACC. NUM. CO PATENT INFORMATION:

in nasal drops, eyedrops, injections, and other topical prepns. are claimed as antiinflammatory agents for treatment of allergic asthma, bronchitis, their formulation examples were given, and their VIP receptor-binding affinity PRIORITY APPLN. INFO.: JP 2003-17909 20030127 AB PACAP and VIP peptide derivs. (I) and their pharmaceutically acceptable salts conjunctivitis, autoimmune disease, atopic dermatitis etc. I were prepared, 20030127 DATE APPLICATION NO. JP 2003-17909 JP 2003-17909 and antiinflammatory action were tested. 20040812 DATE KIND 4 JP 2004224775 PATENT NO.

A61K038-00 ပ္ပ ü

(Pharmacology) A61P029-00 ICS

S

127317-03-7P 134582-09-5P 40077-57-4P, Vasoactive intestinal octacosapeptide (swine) 134582-08-4P Section cross-reference(s): 34, 63

475083-13-7P 

700369-00-2P 700369-02-4P 735327-76-1P 735801-22-6P 700368-94-1P 0368-90-1. 700368-98-5P 700369-vv 735327-76-1P 735801-z-75-4P 735801-26-0P 735327-71-6P 735327-72-7P 700368-96-3P

735801-30-6P 735801-37-3P 735801-27-1P 735801-28-2P 735801-29-3P 735801-31-7P 735801-32-8P 735801-33-9P 735801-34-0P 735801-35-1P 735801-36-2P

735801-23-7P 735801-24-8P 735801-25-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(PACAP and VIP peptide derivs. as antiinflammatory and antiallergic 176785-24-3P 700368-83-8P 700368-85-0P 700368-87-2P 700368-90-7P 700368-96-3P 735327-72-7P 735801-24-8P 735801-25-9P 735801-28-2P 735801-31-7P 735801-32-8P 735801-33-9P 735801-35-1P 735801-36-2P

H

(PACAP and VIP peptide derivs. as antiinflammatory and antiallergic

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L-Leucinamide, L-histidyl-L-seryl-L- $\alpha$ -aspartylglycyl-L-isoleucyl-L-176785-24-3 CAPLUS

Z Z

phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-

Absolute stereochemistry

(CA INDEX NAME)

10/536880

PAGE 1-C

PAGE 1-E

700368-83-8 CAPLUS

Bu-i NH2

Glycinamide, L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-S S

phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

10/536880

PAGE 1-E

L-Lysinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-tseryl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-lanyl-L-arginyl-L-tyrosyl-L-leucyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl-L-leucyl-L-leucyl-L-argin

Absolute stereochemistry.

PAGE 1-C

PAGE 1-D

## 700368-87-2 CAPLUS

L-Argininamide, L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-tyrosyl-C Z

PAGE 1-A

10/536880

PAGE 1-E

RN 700368-90-7 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-d-aspartyl-L-aspartaginyl-L-tyrosyl-Lthreonyl-L-arginyl-L-arginyl-L-arginyl-L-glucyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-islacyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-arginyl-L-d-arginyl-L

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-D

10/536880

PAGE 1-E

700368-96-3 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-argaratyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-targinyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-teucyl-L-alanyl-L-valyl-L-targinyl-L-tyrosyl-L-teucyl-L-alanyl-L-arginyl-L-tyrosyl-L-teucyl-L-alanyl-L-alanyl-L-tyrosyl-L-teucyl-L-alanyl-L-tyros C RN

PAGE 1-C

PAGE 1-E

735327-72-7 CAPLUS Z Z

L-Argininamide, L-histidyl-L-seryl-L-d-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-arginyl-L-taptonyl-L-arginyl-L-tyrosyl-L-tylutaminyl-L-leucyl-L-alanyl-L-varginyl-L-tyrosyl-L-leucyl-L-arginy

10/536880

PAGE 1-A

Absolute stereochemistry.

735801-24-8 CAPLUS Z Z

threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-Lphenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-(CA INDEX NAME) isoleucyl-L-leucylglycyl-L-arginyl- (9CI)

STRUCTURE DIAGRAM IS NOT AVAILABLE 735801-25-9 CAPLUS \* 2 3 5 2 3

L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-Lalanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)  $valyl-L-phenylalanyl-L-threonyl-L-\alpha-aspartyl-L-asparaginyl-L-tyrosyl-$ L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-αspartyl-L-alanyl-L-

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

735801-28-2 CAPLUS R

S

phenylalanyl-L-threonyl-L-α-glutamyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-grutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylgyry-L-arginyl- (9Cl) (CA INDEX NAME) L-Argininamide, L-histidyl-L-seryl-L-lpha-aspartyl-L-alanyl-L-valyl-L-

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 735801-31-7 CAPLUS \* % %

735801-31-7

valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-Larginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-L-Argininamide, L-histidyl-L-seryl-L-lpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-(CA INDEX NAME) leucylglycyl-L-arginyl- (9CI)

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 735801-32-8 CAPLUS

Z Z

 $L-phenylalanyl-L-threonyl-L-\alpha-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-arginyl-L-isoleucyl-L-arginyl-L-isoleucyl-L-arginyl-L-arginyl-L-isoleucyl-L-arginyl-L-isoleucyl-L-arginyl-L-isoleucyl-L-tyrosyl$ L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl-(CA INDEX NAME) L-leucylglycyl-L-arginyl- (9CI)

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* RN

735801-33-9 CAPLUS

seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrosyl-L-leucylglycyl-L-arginyl- (CA INDEX NAME) isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-S

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 735801-35-1 CAPLUS \* KN

L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucylleucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L-arginyl-L-valyl-L-arginyl-L-asparaginyl- (9C1) (CA INDEX NAME) CN

STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* \* \* RN

735801-36-2 CAPLUS

arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L-arginyl-L-valyl-L-arginyl-L-asparaginyl- (9CI) (CA INDEX NAME) L-Argininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-Z

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

2004:492616 CAPLUS Full-text L34 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER:

Pharmaceuticals containing peptides for treatment of retinal diseases 141:47353

Sakamoto, Yuji; Inoue, Atsushi; Yoshida, Masao; Ogami, Masayoshi; Kashimoto, Kazuhisa Senju Pharmaceutical Co., Ltd., Japan; Ito Ham Foods, PATENT ASSIGNEE (S) : INVENTOR (S):

Jpn. Kokai Tokkyo Koho, 21 pp. SOURCE:

CODEN: JKXXAF Japanese FAMILY ACC. NUM. COUNT: DOCUMENT TYPE:

## PATENT INFORMATION:

DATE		20021119	20021119	
APPLICATION NO.		JP 2002-335445	JP 2002-335445	
DATE		20040617		(ARPAT 141:47353
KIND	:	æ		MARPAT
PATENT NO.		JP 2004168697	PRIORITY APPLN. INFO.:	OTHER SOURCE (S):

AB

drops, etc., contain His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg- Tyr-Arg-Arg-Gln-Xi-Ala-Val-Arg-Arg-Tyr-Leu-Ala-Ala-Val-Leu-X2-R (I) (X1 = Leu, Met, Title pharmaceuticals, which are administered by intravitreous injection, eye (X) Nle X; X2 = Gly, Gly-Arg, Gly-Lys, Gly-Lys-Arg, Gly-Arg-Arg, bond; R = NH2, OH; when X2 = bond, then X1 = Met, Nle; when X2 ≠ bond, then X1 = Leu) or their pharmacol. acceptable salts. Thus, intravitreous injection of I (X1 Leu, X2 = Gly-Arg-Arg, R = NH2) (at 10 pM in vitreous humor) significantly improved retinal ischemia-reperfusion injury in rats.

A61P027-02; C07K014-47 A61K038-00 Ω̈

ü

1-11 (Pharmacology)

Section cross-reference(s): 63 ដូ LI

705926-31-4 705926-32 705926-33-6 705926-34-7 705926-31-9 705926-31-0 705926-38-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Peptides for treatment of retinal diseases by topical administration) 705926-33-6 705926-34-7 705926-35-8

II

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(peptides for treatment of retinal diseases by topical administration) 705926-33-6 CAPLUS Glycinamide, L-histidyl-L-seryl-L- $\alpha$ -aspartylglycyl-L-isoleucyl-L-

Z Z

prolyl-L-threonyl-L-a-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-Ltyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-Larginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucyl-

Absolute stereochemistry.

PAGE 1-A

10/536880

PAGE 1-C

PAGE 1-E

705926-34-7 CAPLUS
L-Lyginamide, L-histidyl-L-seryl-L-d-aspartylglycyl-L-isoleucyl-L-prolyt-L-threonyl-L-d-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-d-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-glutaminyl-L-argin

Absolute stereochemistry

PAGE 1-C

PAGE 1-D

PAGE 1-E

705926-15-8 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-d.aspartylglycyl-L-isoleucyl-L-prolyl-L-threonyl-L-d.aspartyl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-C RN

PAGE 1-E

PAGE 1-E

Sustained relaxant action of [Arg15,20,21, L34 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 1998:240334 CAPLUS FULL-text DOCUMENT NUMBER: TITLE:

Yamada, Yumi; Yoshihara, Shigemi; Kashimoto, Kazuhisa; Leul7]-PACAP-27-NH2 on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro

AUTHOR(S):

First Department Pediatrics, Dokkyo University School Medicine, Tochigi, 321-0293, Japan Linden, Anders; Ichimura, Tohju

CORPORATE SOURCE:

Biomedical Research (1998), 19(1), 39-44 CODEN: BRESDS, ISSN: 0388-6107 Biomedical Research Foundation Journal DOCUMENT TYPE: PUBLISHER SOURCE:

Duration of relaxant action of an analog of pituitary adenylate cyclase activating peptide (PACAP)-27, [Arg15,20,21, Leul7]-PACAP-27-NH2, was compared with that of PACAP-27 in the smooth muscle isolated form guinea-pig trachea. The relaxant action was examined on the prolonged contracted state of the addition of the analog, whereas the relaxation induced by PACAP-27, VIP, and PHI reached a maximum by 20 min after the addition and was followed by gradual contraction. Influence of peptidases involved in the smooth muscle the relaxant action with PACAP-27 were significantly potentiated in the presence of peptidase inhibitors, those with the analog were only slightly affected. A conclusion is drawn that the analog has sustained relaxant action sustained action is, at least in part, due to much lower susceptibility of the analog to degradation by peptidases, implying an advantage of the analog in preparation on the peptides was examined using 10  $\mu M$  captopril and 1  $\mu M$  phosphoramidon as peptidase inhibitors. Although the efficacy and duration of Addition of the analog caused concentration-dependent relaxation, both the onset and offset of which were much slower than those with PACAP-27, vascactive intestinal polypeptide (VIP), and peptide histidine isoleucine (PHI). More than 90% of the maximum relaxation was maintained for 6 h after on CCh-induced contraction of the tracheal smooth muscle, and that this smooth muscle, which had been stimulated with carbachol (CCh; 0.1 μM). English application. LANGUAGE: AB Dura

2-5 (Mammalian Hormones) 176785-24-3 SH

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(sustained relaxant action of PACAP-27 analog on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro)

19960606

EP 1996-916331

19970109 19971009 19970924

ES, FI,

Ŗ,

SE

ER, GB, GR, IE, IT, LU, MC, NL, PT, AU 1996-59112 19960606

H

176785-24-3 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(sustained relaxant action of PACAP-27 analog on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro)

PAGE 1-D

10/536880

CAPLUS 176785-24-3

Z Z

phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L  $L\text{-}Leucinamide, \ L\text{-}histidyl\text{-}L\text{-}seryl\text{-}L\text{-}\alpha\text{-}aspartylglycyl\text{-}L\text{-}isoleucyl\text{-}L\text{-}}$ 

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 18 REFERENCE COUNT:

PAGE 1-E

Bu-i | NH2

Peptide bronchodilators Kashimoto, Kazuhisas, Nagano, Yumiko Itoham Foods Inc, Japan Jpn. Kokai Tokkyo Koho, 13 pp. CAPLUS COPYRIGHT 2007 ACS on STN 1997:154810 CAPLUS Full-text 126:152812 CODEN: JKXXAF INVENTOR(S): PATENT ASSIGNEE(S): L34 ANSWER 4 OF 6 ACCESSION NUMBER: DOCUMENT NUMBER: SOURCE:

Japanese 2 FAMILY ACC. NUM. COUNT: PATENT INFORMATION: DOCUMENT TYPE: LANGUAGE:

19950609 19960606 DATE JP 1995-143581 CA 1996-2196308 APPLICATION NO. WO 1996-JP1543 19961217 19961227 19961227 20001017 DATE ΩS A C C A1 KR, . KIND g g CA, JP 08333276 CA 2196308 CA 2196308 WO 9641814 W: AU, RW: AT, AU 9659112 AU 682638 EP 796867 PATENT NO.

		Ľľ,
		IT,
		ΙE,
		쯦,
2		СВ,
0/22086		FR,
	105	FI,
	20031105	ES,
	~	DΚ,
	B1	DE,
		Ğ,
		BE,
	7	AT,
	EP 796867	R: AT,
	EP 7	

LU, MC, NL,

	19960606	•	19960606	1000001
	CN 1996-190882		AT 1996-916331	מוסטבר בססר מנו
	19971001	20031015	20031115	20100001
	ď	æ	H	
PT, SE	CN 1161043	CN 1124283	AT 253590	רטריוטי טני

Thus 15 The human pituitary adenylate cyclase-activating peptides and their pharmaceutical acceptable salts are claimed as bronchodilators. Thus 15 peptides were prepared, and their bronchodilator actions were tested in isolated guinea pig bronchial smooth muscle. 19960606 19951002 US 1997-776815 JP 1995-143581 JP 1995-255370 WO 1996-JP1543 19990105 US 5856303 PRIORITY APPLN. INFO.:

A61K038-22 C07K014-575 ICM C

ΑB

(Pharmacology) ដ

186322-91-8P 186253-19-0P 176785-24-3P 176785-25-4P 186253-15 186767-50-0P 186767-52-2P 186767-54-4P Section cross-reference(s): 34 H

186844-11-1P 186767-64-6P 186767-60-2P 186767-62-4P 186844-13-3P 186844-14-4P 186767-58-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

176785-24-3P 186767-50-0P 186767-52-2P (peptide bronchodilators)

H

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (peptide bronchodilators)

L-Leucinamide, L-histidyl-L-seryl-L- $\alpha$ -aspartylglycyl-L-isoleucyl-L-176785-24-3 CAPLUS S S

 $\label{eq:control} phenylalanyl-L-tyrosyl-L-seryl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-glutyl-L-arginyl-L-arginyl-L-tyrosy$ (CA INDEX NAME)

Absolute stereochemistry

PAGE 1-A

10/536880

PAGE 1-C

. 088965/01

PAGE 1-E

- Bu - i | NH2

Z Z

phenylalanyl-L-threonyl-L-d-aspartyl-L-seryl-L-tyrosyl-L-teryl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-teucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tyrosyl-L 186767-50-0 CAPLUS Glycinamide, L-histidyl-L-seryl-L- $\alpha$ -aspartylglycyl-L-isoleucyl-L-

Absolute stereochemistry.

PAGE 1-C

PAGE 1-E

L-Lysinamide, L-histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-saryinyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-ylutaminyl-L-leucyl-L-arginyl-L-tyrosyl-L-leucyl-L-tyrosyl-L-leucyl-L-arginyl-L-tyrosyl-L-teucyl-L-talanyl-L-valyll-L-tylglycyl- (CA INDEX NAME) C R

PAGE 1-A

PAGE 1-B

PAGE 1-C

10/536880

186767-54-4 CAPLUS
L-Argininamide, L-histidyl-L-seryl-L-d-aspartylglycyl-L-isoleucyl-Lpenylalanyl-L-threonyl-L-d-aspartyl-L-seryl-L-tyrosyl-L-seryl-Larginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyl-L-leucyl-L-alanyl-Lvalyl-L-arginyl-L-tyrosyl-L-leucyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-Lleucylglycyl- (9CI) (CA INDEX NAME) C RN

PAGE 1-C

PAGE 1-D

10/536880

L34 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN ACESSION NUMBER: 1997:103361 CAPLUS Full-text

126:181466 DOCUMENT NUMBER: TITLE:

Structure-activity relationship studies of PACAP-27 and VIP analogs

Kashimoto, K.; Nagano, Y.; Suitani, Y.; Hamanaka, K.; Mizumoto, T.; Tomizaki, K.; Takahata, H.; Nagamoto,

A.; Ohata, A.; et al. ItoHam Foods Inc. Central Research Institute, Ibaraki, 302-01, Japan

CORPORATE SOURCE:

SOURCE:

AUTHOR (S):

Annals of the New York Academy of Sciences (1996), 805 (VIP, PACAP, and Related Peptides), 505-510 CODEN: ANYAA9; ISSN: 0077-6923 New York Academy of Sciences

Journal

PUBLISHER:

To study the role of basic amino acid residues, PACAP-27 and VIP analogs were prepared and their biol. activity was measured. Their is a relationship between the duration of activity in preventing carbachol-induced bronchoconstriction in guinea pigs and the basicity of the peptides. English DOCUMENT TYPE: LANGUAGE: AB

2-2 (Mammalian Hormones) CC

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationship studies of PACAP-27 and VIP analogs) 127317-03-7, 40077-57-4, Vasoactive intestinal octacosapeptide (pig) Human PACAP-27 147262-52-0 176785-24-3 176785-25-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological ly, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationship studies of PACAP-27 and VIP analogs) 176785-24-H

CAPLUS

176785-24-3

valy1-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-(9CI) (CA INDEX NAME)  $phenylalanyl-L-threonyl-L-\alpha-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-seryl-L-arginyl-L-a$ L-Leucinamide, L-histidyl-L-seryl-L- $\alpha\text{-aspartylglycyl-L-isoleucyl-L-}$ C. R.

PAGE 1-A

PAGE 1-B

PAGE 1-C

10/536880

PAGE 1-E

Bu-i

/ NH2

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT REFERENCE COUNT:

Structure-activity relationship studies of PACAP-27 
 L34
 ANSWER 6 OF 6
 CAPLUS
 CODYRIGHT
 2007 ACS on STN

 ACCESSION NUMBER:
 1996:286008
 CAPLUS
 Full-text

 DOCUMENT NUMBER:
 124:331662
 TITLE:

and VIP analogs

Kashimoto, Kazuhisa; Nagano, Yumiko; Suitani, Yoshihiko; Hamanaka, Kazuya; Mizumoto, Takahiro; Tomizaki, Kin-ya; Takahata, Hikari; Nagamoto, Akiko; AUTHOR (S):

Ohata, Akiko; et al. ItoHam Foods INC, Central Research Institute, Ibaraki, 302-01, Japan Peptide Chemistry (1996), Volume Date 1995, 33rd, CORPORATE SOURCE:

361-364 SOURCE:

CODEN: PECHDP, ISSN: 0388-3698 Protein Research Foundation Journal DOCUMENT TYPE:

We obtained the results that the duration of tracheal relaxant activity varied with modification of PACAP-27 and VIP mols. The degree of the duration of activities was BM-analog > M-analog > native compound These results show that there is a relation between the duration of activity and basicity of peptide caused by the number of basic amino acid residues in the sequence. English LANGUAGE: AB

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Structure-sark); USES (Uses) 1-3 (Pharmacology) 37221-79-7, VIP 128606-20-2, Pept: PACAP 27 176785-24-3 176785-25-4 CC

(structure-activity relationship studies of PACAP-27 and VIP analogs)

116

II

In6785-24-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Biological study); USES (Uses)
(structure-activity relationship studies of PACAP-27 and VIP analogs)
176785-24-3 CAPLUS

Z Z

phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-gCI) (CA INDEX NAME)  $L\text{-Leucinamide, }L\text{-histidyl-}L\text{-seryl-}L\text{-}\alpha\text{-aspartylglycyl-}L\text{-isoleucyl-}L\text{-}$ 

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

NH2

10/536880

PAGE 1-D

Bu-i

PAGE 1-E

/ NH2

፤

77

SAM L10 'MEDLINE, EMBASE, BIOSIS' PLU=ON PLU=ON PLU=ON PLU=ON 1 SEA ABB=ON PLU=ON 20 SEA ABB=ON PLU=ON 25 SEA ABB=ON PLU=ON ANSWERS '1-25' PLU=ON PLU=ON PLU=ON PLU=ON PLU=ON PLU=ON 0 SEA SUB=L13 SSS 11 SEA SSS FUL L10 D STAT QUE L30 42 SEA ABB=ON 20 DUP REM L30 13 SEA ABB=ON 16 SEA ABB=ON 23 SEA ABB=ON 62 SEA ABB=ON CAPLUS' ENTERED 3 SEA ABB=ON ABB=ON ABB=ON ABB=ON ABB=ON ABB=ON ABB=ON D COST 2952 SEA A 4255 SEA A 118 SEA A SEA 9 SEA 1 SEA MEDLINE, 30 JAN 2007 FILE FILE FILE FILE FILE FILE FILE FILE FILE L30 L14 L16 L17 L19 L19 L20 L21 L22 L23 L23 L24 L26 L27 L28 L29 L32 133 16 SEA ABB=ON PLU=ON (127317-03-7/BI OR 134582-08-4/BI OR 131061-48-4/BI OR 3721-79-7/FIB OR 40077-57-4/BI OR 475083-13-7
181 OR 700368-76-9/BI OR 700368-79-2/BI OR 700368-81-6/BI OR 700368-81-8/BI OR 700368-82-9/BI OR 700368-87-2/BI OR 700368-89-5/BI OR 700368-87-7/BI OR 700368-89-5/BI OR 700368-87-7/BI OR 700368-98-5/BI OR 700368-90-02-4/BI OR 700368-98-5/BI OR 700368-31-7/BI OR 702686-31-5/BI OR 702686-31-5/BI OR 702686-31-5/BI OR 702686-31-5/BI OR 702686-31-5/BI OR 702686-31-5/BI OR 702686-31-8/BI OR 702686-31-8/BI OR 702686-52-0/BI OR 702686-53-1/BI OR 702686-59-1/BI OR 702686-59-6/BI OR 702686-59-1/BI OR 702686-59-6/BI OR 702686 FILE 'REGISTRY' ENTERED AT 10:26:42 ON 30 JAN 2007 54 SEA ABB=ON PLU=ON HSDA[IV]FT[DEA] [SND]Y[ST]R[YL]RRQLAVRRYLAA/ FILE 'REGISTRY' ENTERED AT 10:20:41 ON 30 JAN 2007 389 SEA ABB-ON PLU-ON HSDA[IV]FT[DEA][SND]Y[ST]R[YL]RRQLAVRRYLAA/ FILE 'REGISTRY' ENTERED AT 10:24:18 ON 30 JAN 2007 'REGISTRY' ENTERED AT 10:30:11 ON 30 JAN 2007 'REGISTRY' ENTERED AT 10:30:32 ON 30 JAN 2007 'REGISTRY' ENTERED AT 12:09:52 ON 30 JAN 2007 'STNGUIDE' ENTERED AT 10:31:59 ON 30 JAN 2007 'REGISTRY' ENTERED AT 12:08:18 ON 30 JAN 2007 'CAPLUS' ENTERED AT 10:30:24 ON 30 JAN 2007 4 SEA ABB=ON PLU=ON L8 'CAPLUS' ENTERED AT 12:09:29 ON 30 JAN 2007 E US2005-536880 /APPS FILE 'CAPLUS' ENTERED AT 10:24:06 ON 30 JAN 2007 349 SEA ABB=ON PLU=ON L1 FILE 'CAPLUS' ENTERED AT 10:26:18 ON 30 JAN 2007 'CAPLUS' ENTERED AT 10:29:23 ON 30 JAN 2007 4 SEA ABB-ON PLU-ON L6 1 SEA ABB=ON PLU=ON US2005-536880 /AP (FILE 'HOME' ENTERED AT 10:20:09 ON 30 JAN 2007) AMI?/NTE L1 AND L3 30 SEA ABB=ON PLU=ON L6 AND L3 7 PLU=ON 266 SEA ABB=ON PLU=ON STRUCTURE UPLOADED 0 SEA SSS SAM L10 113096 SEA ABB=ON 130 SEA ABB=ON E A/NTE -> d his full

FILE

53

2 2

16

Ľ

FILE

2

FILE

2

FILE

FILE

FILE

111

FILE

112

FILE

113

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, TOXCENTER' ENTERED AT 12:22:17 ON (L19 OR L20 OR L21) AND (L16 OR L9) ENTERED AT 12:21:41 ON 30 JAN 2007 EMBASE, BIOSIS' ENTERED AT 12:15:53 ON 30 JAN 2007 32 DUP REM L32 L30 L29 (55 DUPLICATES REMOVED) 4 TERMS 2007 'TOXCENTER' ENTERED AT 12:21:53 ON 30 JAN 2007 D STAT QUE L29 177 'REGISTRY' ENTERED AT 12:14:39 ON 30 JAN 2007 'REGISTRY' ENTERED AT 12:18:30 ON 30 JAN 2007 FILE 'REGISTRY' ENTERED AT 12:24:03 ON 30 JAN 2007 'STNGUIDE' ENTERED AT 12:16:16 ON 30 JAN 2007 ANSWERS '1-12' FROM FILE MEDLINE 'CAPLUS' ENTERED AT 12:21:11 ON 30 JAN 2007 D STAT QUE L24 D STAT QUE L25 ANSWERS '14-20' FROM FILE BIOSIS ANSWERS '27-32' FROM FILE BIOSIS AT 12:11:48 ON 30 JAN 2007 ONOUE S?/AU L19 AND (L20 OR L L20 AND L21 FROM FILE CAPLUS TOXCENTER' ENTERED AT 12:15:18 ON 30 JAN L9 OR L16 MATSUMOTO A?/AU ANSWER '26' FROM FILE MEDLINE (22 DUPLICATES REMOVED) D IBIB ABS HITIND HITSTR L33 1-25 D IALL L33 26-32 ANSWER '13' FROM FILE EMBASE (L22 OR L23) OR L25) L16 AND L12 D L8 RN CN SQL NTE LC KWIC 1-30 (L22 OR L23 ENDO K?/AU SEA ABB=ON PLU=ON L6 OR L15 ANALYZE PLU=ON L26 1- LC : SAVE TEMP L15 HA880STR10L/A (L24 L26

119

7/BI OR 703414-61-3/BI OR 735327-72-7/BI)

US' ENTERED AT 12:24:08 ON 30 JAN 2007 D STAT QUE L9 D STAT QUE L16 FILE 'CAPLUS'

NOT L32 (L9 OR L16) 6 SEA ABB=ON PLU=ON

L34

'TOXCENTER' ENTERED AT 12:24:42 ON 30 JAN 2007 0 SEA ABB=ON PLU=ON L28 NOT L29 D STAT QUE L28 FILE

135

FILE 'CAPLUS' ENTERED AT 12:25:57 ON 30 JAN 2007 D IBIB ABS HITIND HITSTR L34 1-6

FILE 'TOXCENTER' ENTERED AT 12:25:59 ON 30 JAN 2007

FILE HOME

Property values tagged with IC are from the ZIC/VINITI data file FILE REGISTRY

provided by InfoChem

29 JAN 2007 HIGHEST RN 918776-45-1 29 JAN 2007 HIGHEST RN 918776-45-1 DICTIONARY FILE UPDATES: STRUCTURE FILE UPDATES:

New CAS Information Use Policies, enter HELP USAGETERMS for details.

ISCA INFORMATION NOW CURRENT THROUGH June 30, 2006

note that search-term pricing does apply when conducting SmartSELECT searches REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE CAPLUS

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December strictly prohibited

VOL 146 ISS 6 (20070129/ED) FILE COVERS 1907 - 30 Jan 2007 FILE LAST UPDATED: 29 Jan 2007 Effective October 17, 2005, revised CAS Information Use Policies apply They are available for your review at:

FILE STUGUIDE PILE CONTAINS CURRENT INFORMATION.

10/536880

LAST RELOADED: Jan 26, 2007 (20070126/UP).

FILE TOXCENTER

FILE COVERS 1907 TO 23 Jan 200,7 (20070123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MeSH terms.and See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2007 vocabulary.

FILE MEDLINE

FILE LAST UPDATED: 27 Jan 2007 (20070127/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE COVERS 1974 TO 30 Jan 2007 (20070130/ED)

SDI frequency remains weekly (default) EMBASE is now updated daily.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS FILE COVERS 1969 TO DATE. CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 24 January 2007 (20070124/ED)

٨